Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 24387. Отображено 100.
23-02-2012 дата публикации

Diacylethylenediamine compound

Номер: US20120046292A1
Принадлежит: Astellas Pharma Inc

[Problem] A compound which is useful as an anti-obesity agent is provided. [Means for Solution] The present inventors have investigated a compound having a DGAT1 inhibitory action, which is promising as an active ingredient of a pharmaceutical composition for treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases, and as a result, they have found that the diacylethylenediamine compound of the present invention has an excellent DGAT1 inhibitory action, thereby completing the present invention. That is, the diacylethylenediamine compound of the present invention has a DGAT1 inhibitory action, and can be therefore used as an agent for preventing and/or treating obesity, type II diabetes mellitus, fatty liver, and diseases associated with these diseases.

Подробнее
22-03-2012 дата публикации

Metallo-beta-lactamase inhibitors

Номер: US20120071457A1
Принадлежит: Individual

A new metallo-β-lactamase inhibitor which acts as a medicament for inhibiting the inactivation of β-lactam antibiotics and recovering anti-bacterial activities is disclosed. The maleic acid derivatives having the general formula (I) have metallo-β-lactamase inhibiting activities. It is possible to recover the anti-bacterial activities of β-lactam antibiotics against metallo-β-lactamase producing bacteria by combining the compound of the general formula (I) with β-lactam antibiotics.

Подробнее
03-05-2012 дата публикации

Carbamoyl Compounds as DGAT1 Inhibitors 190

Номер: US20120108602A1
Принадлежит: AstraZeneca AB

DGAT-1 inhibitor compounds of formula (1), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is ═0; Ring B is optionally substituted 1,4-phenylene; Y 1 is a direct bond or —O—; Y 2 is —(CH 2 ) r — wherein r is 2 or 3; n is 0 or n is 1 when Y 1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or —O—; p is 0, 1 or 2 and when p is 1 or 2 R A1 and R A2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.

Подробнее
10-05-2012 дата публикации

Compound inhibiting in vivo phosphorus transport and medicine containing the same

Номер: US20120115851A1
Принадлежит: Kyowa Hakko Kirin Co Ltd

An objective of the present invention is to provide compounds that can effectively suppress the concentration of phosphorus in serum to effectively prevent or treat diseases induced by an increase in concentration of phosphate in serum. The compounds according to the present invention are compounds represented by formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein A represents an optionally substituted five- to nine-membered unsaturated carbocyclic moiety or a five- to nine-membered unsaturated heterocyclic moiety, and represents a single bond or a double bond, R 5 represents optionally substituted aryl or the like, Z represents —N═CHR 6 R 7 or the like, R 6 and R 7 represent H, optionally substituted alkyl, optionally substituted aryl or the like, R 101 and R 102 together form ═O, and R 103 and R 104 represent H, or R 101 and R 104 together from a bond, and R 102 and R 103 together form a bond.

Подробнее
10-05-2012 дата публикации

N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation

Номер: US20120115915A1
Принадлежит: Harvard College

Compositions and methods for inhibiting translation initiation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using N,N′-diarylureas and/or N,N′-diarylthiourea compounds are described.

Подробнее
10-05-2012 дата публикации

Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors

Номер: US20120116091A1
Принадлежит: Chiesi Farmaceutici SpA

Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.

Подробнее
31-05-2012 дата публикации

Substituted Esters as Cannabinoid-1 Receptor Modulators

Номер: US20120135975A1
Принадлежит: Merck and Co Inc

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.

Подробнее
07-06-2012 дата публикации

Compounds as bradykinin b1 antagonists

Номер: US20120142695A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of the formula I wherein n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and X are defined as described in the specification, which are bradykinin B1 antagonists, and their use as medicaments.

Подробнее
28-06-2012 дата публикации

Glucagon Receptor Modulators

Номер: US20120165343A1
Принадлежит: PFIZER INC

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R 1 , R 2 , R 3 , A 1 , A 2 , A 3 , A 4 , L, B 1 , B 2 , B 3 and B 4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Подробнее
12-07-2012 дата публикации

Hdac inhibitors

Номер: US20120178783A1
Принадлежит: Lixte Biotechnology Inc

This invention provides the compound having the structure wherein n is 1-10; X is C—R 11 or N; wherein R 11 is H, OH, SH, F, Cl, SO 2 R 7 , NO 2 , trifluoromethyl, methoxy, or CO—R 7 , wherein R 7 is alkyl, alkenyl, alkynyl, C 3 -C 8 cycloalkyl, or aryl; Z is R 2 is H or NR 3 R 4 , wherein R 3 and R 4 are each independently H, C 1 -C 6 alkyl, or C 3 -C 8 cycloalkyl; R 5 is OH or SH; and R 6 , R 12 , R 13 , and R 14 are each independently H, OH, SH, F, Cl, SO 2 R 15 , NO 2 , trifluoromethyl, methoxy, or CO—R 15 , wherein R 15 is alkyl, alkenyl, alkynyl, C 3 -C 8 cycloalkyl, or aryl, or a salt of the compound, which is useful in the treatment of tumors.

Подробнее
19-07-2012 дата публикации

Substituted nicotinamides as kcnq2/3 modulators

Номер: US20120184550A1
Принадлежит: GRUENENTHAL GmbH

Substituted nicotinamides, processes for their preparation, medicaments comprising these compounds and methods of using these compounds to treat pain, epilepsy, urinary incontinence, anxiety, dependency, mania, bipolar disorders, migraine, cognitive diseases, and/or dystonia-associated dyskinesias.

Подробнее
26-07-2012 дата публикации

Process for the preparation of 4-amino-3-chloro-5-fluoro-6-(substituted) picolinates

Номер: US20120190858A1
Принадлежит: DOW AGROSCIENCES LLC

4-Amino-3-chloro-5-fluoro-6-(substituted)picolinates are conveniently prepared from 3,4,5,6-tetrachloropicolinonitrile by a series of steps involving fluorine exchange, amination, reaction with hydrazine, halogenation, hydrolysis and esterification, and transition metal assisted coupling.

Подробнее
26-07-2012 дата публикации

Process for the preparation of 4-amino-5-fluoro-3-halo-6-(substituted)picolinates

Номер: US20120190860A1
Принадлежит: DOW AGROSCIENCES LLC

4-Amino-5-fluoro-3-halo-6-(substituted)picolinates are conveniently prepared from 4,5,6-trichloropicolinates by a series of steps involving fluorine exchange, amination, halogen exchange, halogenation and transition metal assisted coupling.

Подробнее
02-08-2012 дата публикации

Tertiary amide orexin receptor antagonists

Номер: US20120196901A1
Принадлежит: Merck Sharp and Dohme LLC

The present invention is directed to tertiary amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Подробнее
02-08-2012 дата публикации

Sulfoximines as kinase inhibitors

Номер: US20120196902A1
Принадлежит: Allergan Inc

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

Подробнее
09-08-2012 дата публикации

Substituted 4-aminocyclohexane derivatives

Номер: US20120202810A1
Принадлежит: GRUENENTHAL GmbH

The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.

Подробнее
23-08-2012 дата публикации

Viral polymerase inhibitors

Номер: US20120214783A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds of formula I: wherein X, R 2 , R 3 , R 3a , R 3b , R 5 and R 6 are defined herein, are useful as inhibitors of the hepatitis C virus NS5B polymerase.

Подробнее
23-08-2012 дата публикации

New compounds, pharmaceutical compositions and uses thereof

Номер: US20120214785A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Подробнее
06-09-2012 дата публикации

Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease

Номер: US20120225890A1
Принадлежит: ProteoTech Inc

Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Подробнее
04-10-2012 дата публикации

Pyridinecarboxamides, useful-plant-protecting composition comprising them and processes for their preparation and their use

Номер: US20120252670A1
Принадлежит: Individual

Compounds of the formula (I), or salts thereof, in which R 1 to R 4 are as defined in formula (I) of claim 1 are suitable as useful-plant-protecting agents for reducing or preventing harmful effects of agrochemicals on the useful plants and their method of preparation are described.

Подробнее
18-10-2012 дата публикации

PROCESS FOR MAKING (R) -3-(2,3-DIHYDROXYPROPYL)-6-FLUORO-5-(2-FLOURO-4-IODOPHENYLAMINO)-8-METHYLPYRIDO[2,3-d]PYRIMIDINE-4,7(3H,8H)-DIONE AND INTERMEDIATES THEREOF

Номер: US20120264967A1
Принадлежит: Takeda Pharmaceutical Co Ltd

The present invention relates generally to processes of making (R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione, intermediates thereof, and a process for making a particular polymorph of (R)-3-(2,3-Dihydroxypropyl)-6-fluoro-5-(2-fluoro-4-iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione.

Подробнее
25-10-2012 дата публикации

Adamantyl diamide derivatives and uses of same

Номер: US20120270873A1
Принадлежит: H Lundbeck AS

The present invention provides adamantyl-diamide derivatives of formula (I): wherein R 1 and R 2 are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same.

Подробнее
22-11-2012 дата публикации

3-Arylamino Pyridine Derivatives

Номер: US20120295889A1
Принадлежит: MERCK SERONO SA

The invention provides novel, substituted 3-arylamino pyridine compounds pharmaceutically acceptable salts, solvates and prodrug compounds thereof, wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Also disclosed is the use of such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and pharmaceutical compositions containing such compounds.

Подробнее
13-12-2012 дата публикации

Chiral Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex

Номер: US20120316066A1
Принадлежит: Intrexon Corp

The present invention provides diacylhydrazine ligands and chiral diacylhydrazine ligands for use with ecdysone receptor-based inducible gene expression systems. Thus, the present invention is useful for applications such as gene therapy, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable. An advantage of the present invention is that it provides a means to regulate gene expression and to tailor expression levels to suit the user's requirements.

Подробнее
27-12-2012 дата публикации

Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer

Номер: US20120329836A1
Принадлежит: Ohio State University

Disclosed herein is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and the ester and amide prodrugs thereof, that can stabilize hypoxia inducible factor-2 alpha (HIF-2α) and thereby provide a method for treating cancer. Further disclosed are compositions which comprise {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]-amino}acetic acid and/or a prodrug thereof which can be used to treat cancer.

Подробнее
31-01-2013 дата публикации

Agent for preventing or treating diseases accompanied by urinary pain

Номер: US20130030006A1
Принадлежит: Astellas Pharma Inc

[Problem] Provided is an agent for preventing or treating diseases accompanied by urinary pain. [Means for Solution] A pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound or a salt thereof was confirmed to have not only an action of increasing effective bladder capacity but also an analgesic action against bladder pain and testis pain, based on FAAH inhibitory action. Accordingly, the pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound or a salt thereof can be used for preventing or treating interstitial cystitis/bladder pain syndrome and/or chronic nonbacterial prostatitis/chronic pelvic pain syndrome.

Подробнее
14-03-2013 дата публикации

N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides

Номер: US20130065911A1
Принадлежит: Hoffmann La Roche Inc

The present invention relates to compounds of the formula wherein R 1 to R 3 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

Подробнее
21-03-2013 дата публикации

HYDROXYPYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE FOR TREATING PROLIFERATIVE DISEASES

Номер: US20130072526A1
Принадлежит: BIOTHERYX INC.

Provided herein are hydroxypyridone derivatives, for example, a compound of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease. 2. The method of claim 1 , wherein Z is a bond.3. The method of claim 1 , wherein m is 2.4. The method of claim 1 , wherein n is 0.6. The method of claim 1 , wherein Ris Calkyl.7. The method of claim 1 , wherein Ris Caryl.8. The method of claim 7 , wherein Ris phenyl.9. The method of claim 1 , wherein Ris hydrogen.10. The method of claim 1 , wherein Ris hydrogen.11. The method of claim 1 , wherein Ris —C(R).12. The method of claim 11 , wherein Ris hydrogen.13. The method of claim 11 , wherein Ris deuterium.14. The method of claim 11 , wherein Ris fluoro.15. The method of claim 1 , wherein Ris methyl or trifluoromethyl.16. The method of claim 1 , wherein Ris hydrogen.17. The method of claim 1 , wherein Ris —C(O)Caryl; R claim 1 , R claim 1 , and Rare hydrogen; Ris Calkyl; m is 2; and n is 0; where the alkyl and aryl are optionally substituted with one or more substituents Q.18. The method of claim 1 , wherein Ris benzoyl; R claim 1 , R claim 1 , and Rare hydrogen; Ris methyl; m is 2; and n is 0; where the methyl and benzoyl are optionally substituted with one or more substituents Q.19. The method of claim 1 , wherein Ris benzoyl; R claim 1 , R claim 1 , and Rare hydrogen; Ris methyl or trifluoromethyl; m is 2; and n is 0.21. The method of claim 20 , wherein the compound is 6-cyclohexyl-4-methyl-2-oxopyridin-1(2H)-yl benzoate claim 20 , or a tautomer claim 20 , a mixture of two or more tautomer claim 20 , or an isotopic variant thereof; or a pharmaceutically acceptable salt claim 20 , solvate claim 20 , hydrate claim 20 , or prodrug thereof.22. The method of claim 1 , wherein the cancer is drug resistant.23. The method of claim 1 , wherein the cancer is leukemia.24. The method of claim 1 , wherein the cancer ...

Подробнее
18-04-2013 дата публикации

DUAL-ACTING ANTIHYPERTENSIVE AGENTS

Номер: US20130096162A1
Принадлежит:

The invention is directed to compounds having the formula: 2. The compound of claim 1 , wherein r is 1.3. (canceled)5. The compound of claim 4 , wherein Ris selected from —COOH claim 4 , —SONHR claim 4 , and tetrazol-5-yl.711-. (canceled)12. The compound of claim 1 , wherein Ris selected from —Calkyl and —Calkylene-O—Calkylene-R claim 1 , where Ris —Calkyl.13. The compound of claim 12 , wherein Ris selected from —Calkyl and —O—Calkyl.14. The compound of claim 1 , wherein X is —Calkylene- claim 1 , 1 to 4-CH-moieties in the alkylene are replaced with a —NR—C(O)— or —C(O)—NR— moiety claim 1 , and Ris selected from H and —OH.15. The compound of wherein X is selected from: —C(O)NH—; —CH—NHC(O)—; —C(O)NH—CH—; —C(O)NH—NHC(O)—; —CH═C(—CH-2-thiophene)-C(O)NH—; —(CH)—NHC(O)—; —C(O)NH—CH—CH(COOH)—CH—; —C(O)NH—CH(benzyl)-CH—NHC(O)—; —C(O)NH—CH(benzyl)-CH—C(O)NH—; —CH—NHC(O)—CH—NHC(O)—; —CH—NHC(O)-cyclohexylene-NHC(O)—; —CH—N(OH)C(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—CH—CH(COOH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —C(O)NH—(CH)—C(O)N(OH)—CH—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—NHC(O)—; —CH—NHC(O)—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —C(O)NH—(CH)—NHC(O)—CH—NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —C(O)NH—(CH)—CH(COOH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —C(O)NH—(CH)—NHC(O)—CH—NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)—; —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—; —C(O)NH—(CH)—NHC(O)-cyclohexylene-NHC(O)—; and —CH—NHC(O)—(CH)—NHC(O)-cyclohexylene-NHC(O)—.16. The compound of claim 15 , wherein X is selected from —C(O)NH— and —CH—NHC(O)—.17. The compound of claim 1 , wherein Ris selected from —Calkylene-SR claim 1 , —Calkylene-C(O)NRR claim 1 , —Calkylene-NR—C(O)R claim 1 , —NH—Calkylene-P(O)(OR) claim 1 , —Calkylene-P(O)ORR claim 1 , —Calkylene-CHR—COOH claim 1 , and —Calkylene-C(O)NR—CHR—COOH; Ris H claim 1 , Ris —OH claim 1 ...

Подробнее
25-04-2013 дата публикации

COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS

Номер: US20130102597A1
Принадлежит: INTERMUNE, INC.

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. 3. The method of claim 2 , wherein{'sup': '1', 'Ris selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, cyano, sulfonamido, halo, alkenylenearyl, and heteroaryl;'}{'sup': 2', '2', '1, 'sub': 3', '2', '2', '2', '2', '2, 'Ris selected from the group consisting of aryl; unsubstituted heteroaryl; heteroaryl substituted with one or more substituents selected from halo, unsubstituted alkyl, alkenyl, OCF, NO, CN, NC, OH, alkoxy, haloalkoxy, amino, COH, and COalkyl; haloalkylcarbonyl; cycloalkyl; hydroxylalkyl; sulfonamide; unsubstituted cycloheteroalkyl and cycloheteroalkyl substituted with one to three substituents independently selected from alkyleneOH, C(O)NH, NH, aryl, haloalkyl, halo, and OH; or Rand Rtogether form an optionally substituted 5-membered nitrogen-containing heterocyclic ring;'}{'sup': '4', 'Ris selected from the group consisting of hydrogen, haloalkyl, alkoxy, alkenyl, and alkenylenearyl; and'}{'sup': '5', 'Xis hydrogen.'}4. The method of claim 1 , wherein one of X claim 1 , X claim 1 , and Xis not hydrogen.5. The method of claim 4 , wherein Ris selected from the group consisting of aryl; unsubstituted heteroaryl; heteroaryl substituted with one or more substituents selected from halo claim 4 , unsubstituted alkyl claim 4 , alkenyl claim 4 , OCF claim 4 , NO claim 4 , CN claim 4 , NC claim 4 , OH claim 4 , alkoxy claim 4 , haloalkoxy claim 4 , amino claim 4 , COH ...

Подробнее
25-04-2013 дата публикации

BIARYL OXYACETIC ACID COMPOUNDS

Номер: US20130102609A1
Принадлежит: LIGAND PHARMACEUTICALS INC.

The present invention provides biaryl oxyacetic acid compounds which may be useful for treating inflammatory disorders, including disorders affecting the respiratory system and skin. The compounds provided include those of the general formula I: 2. A compound or salt according to wherein R claim 1 , R claim 1 , Rand Rare each independently selected from hydrogen and methyl.3. (canceled)4. A compound or salt according to claim 1 , wherein Ris selected from hydrogen claim 1 , methyl claim 1 , ethyl claim 1 , propyl and isopropyl.5. (canceled)6. A compound or salt according to claim 1 , wherein Ris selected from aryl and heteroaryl claim 1 , each optionally substituted with one to four substituents independently selected from halogen claim 1 , cyano claim 1 , (C-C) haloalkyl claim 1 , (C-C) alkoxy claim 1 , (C-C) haloalkoxy claim 1 , (C-C) alkyl claim 1 , and (C-C) alkylsulfonyl.9. A compound or salt according to claim 8 , wherein Ris selected from hydrogen claim 8 , methyl claim 8 , fluoro claim 8 , chloro claim 8 , cyano claim 8 , —CFand methoxy; and Ris selected from hydrogen claim 8 , fluoro claim 8 , chloro claim 8 , methyl claim 8 , methoxy claim 8 , cyano claim 8 , —CFand —SOCH.10. A compound or salt according to wherein Rand Rare each independently selected from fluoro claim 9 , chloro claim 9 , methoxy and hydrogen.11. (canceled)13. A compound or salt according to wherein Ris selected from naphthyl claim 6 , pyridinyl and quinolinyl claim 6 , each optionally substituted with one to four substituents independently selected from halogen claim 6 , cyano claim 6 , (C-C) haloalkyl claim 6 , (C-C) alkoxy claim 6 , (C-C) haloalkoxy claim 6 , (C-C) alkyl and alkylsulfonyl.14. A compound or salt according to claim 1 , wherein Rand Rare each hydrogen.15. A compound or salt according to claim 1 , wherein A is selected from phenyl claim 1 , pyridinyl claim 1 , benzimidazolyl claim 1 , quinolinyl claim 1 , indolyl claim 1 , pyrimidinyl and imidazopyridinyl.16. A compound ...

Подробнее
25-04-2013 дата публикации

Method for the preparation of cis-1,2-diols in the kilogram scale

Номер: US20130102640A1
Принадлежит: Merck Patent GmBH

The present invention relates to the scale up of the preparation of cis-1,2-diols of formula I from the gram to the kilogram scale.

Подробнее
25-04-2013 дата публикации

ALKYNYL-DERIVATIZED CAP ANALOGS, PREPARATION AND USES THEREOF

Номер: US20130102655A1
Принадлежит: LIFE TECHNOLOGIES CORPORATION

Alkynyl-derivatized cap analogs, alkynyl-modified capped RNA, 1,4-disubstituted triazole-derivatized capped RNA, methods of preparation, methods of isolation, and uses thereof are provided. The “click” modification facilitates detection and isolation of capped RNAs and the 1,4-disubstituted triazole derivatives formed by the “click” reaction are useful for producing RNA transcripts and encoded protein. 1. A composition comprising an alkynyl-derivatized cap analog having the structure:{'sub': '3', 'sup': '7,3′-O-alkynyl', 'RG[5′]p[p]np[5′]G,'}{'sub': '3', 'sup': '7,3′-O-alkynyl', 'RG[5′]p[p]np[5′]A,'}{'sub': '3', 'sup': '7,2′-O-alkynyl', 'b': '5', 'RG[′]p[p]np[5′]G,'}{'sub': '3', 'sup': '7,2′-O-alkynyl', 'b': '5', 'RG[′]p[p]np[5′]A,'} [{'sub': '3', 'Ris alkyl or arylalkyl,'}, 'the alkynyl moiety comprises 3-24 carbon atoms, a terminal alkyne, and is optionally substituted,', 'n is 1, 2, or 3,', 'A is adenosine, and', 'G is guanosine., 'wherein'}, 'or a salt thereof,'}2. A composition comprising RNA having a cap analog of covalently bonded thereto.4. The composition of claim 3 , wherein Rcomprises O(CH)C≡CH and m is 1 to 6 claim 3 , and Rcomprises OH.5. The composition of claim 3 , wherein Rcomprises O(CH)C≡CH and m is 1 to 6 claim 3 , and Rcomprises OH.6. The composition of claim 4 , wherein m is 1.7. The composition of wherein the alkyl is methyl claim 3 , ethyl claim 3 , propyl claim 3 , isopropyl claim 3 , butyl or isobutyl.8. The composition of attached to the 5′ end of an RNA molecule.9. The composition of wherein the RNA molecule is a mRNA molecule.10. A method of producing alkynyl-modified capped RNA comprising: contacting a nucleic acid substrate with a RNA polymerase and the alkynyl-derivatized cap analog of in the presence of nucleotide triphosphates under conditions and for a time to produce alkynyl-modified capped RNA.11. The method of further comprising contacting the alkynyl-modified capped RNA with an azide-derivatized moiety to form a 1 claim 10 ,4- ...

Подробнее
25-04-2013 дата публикации

THIONATION PROCESS AND A THIONATING AGENT

Номер: US20130102774A1
Принадлежит: Vironova AB

A process for transforming a group >C═O (I) in a compound into a group >C═S (II) or into a tautomeric form of group (II) in a reaction giving a thionated reaction product, by use of crystalline PS.2 CHN as a thionating agent. A thionating agent which is crystalline PS.2 CHN. 1. A process for transforming a group >C═O (I) in a compound into a group >C═S (II) or into a tautomeric form of group (II) in a reaction giving a thionated reaction product , by use of crystalline PS.2 CHN as a thionating agent.2. A process according to claim 1 , wherein the thionating agent and the compound are allowed to react with each other in a liquid solvent medium for the compound and for the thionating agent.3. The process according to claim 1 , wherein the liquid solvent medium comprises pyridine claim 1 , a C1-C3 alkylnitrile claim 1 , a cyclic sulfone and/or a C1-C3 dialkylsulfone.4. The process according to claim 1 , wherein the liquid solvent medium comprises pyridine claim 1 , sulfolane claim 1 , dimethyl sulfone and/or acetonitrile.5. The process according to claim 1 , wherein the reaction is performed at a temperature of 60° C. to 180° C.6. The process according to claim 5 , wherein the reaction is performed at temperature of 115° C. to 175° C.7. The process according to claim 1 , wherein the compound comprises a group (I) that is present in an amide function.8. The process according to claim 1 , wherein the compound comprises a group (I) that is present in a ketone function.9. The process according to claim 1 , wherein the thionating agent is used at a molar ratio to the group (I) to be transformed of 1 mole PS.2 CHN per 1-4 moles of group (I).10. The process according to claim 1 , comprising separating the thionated reaction product from the reaction.11. The process according to claim 10 , wherein water is added to the reaction and the thionated reaction product is separated as a solid material claim 10 , by precipitation or crystallization.12. A thionating agent which is ...

Подробнее
02-05-2013 дата публикации

Method of ameliorating oxidative stress and supplementing the diet

Номер: US20130108605A1

A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of lipid soluble, hydrophobic active compounds having a chemical structure: wherein R 1 is an aromatic backbone and R 2 is a sulfur containing ligand. Through formation of disulfide linkages other moieties can be attached to R 2 converting the hydrophobic base into a water soluble entity, for ease of delivery, which can be reconverted back to the original compound by biochemical reduction in the blood stream.

Подробнее
02-05-2013 дата публикации

C7-Fluoro Substituted Tetracycline Compounds

Номер: US20130109657A1
Принадлежит: Tetraphase Pharmaceuticals Inc

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

Подробнее
02-05-2013 дата публикации

HETERO-SUBSTITUTED ACETANILIDE DERIVATIVES AS ANALGESIC AGENTS

Номер: US20130109863A1
Принадлежит: Janssen Pharmaceutica N.V.

Hetero-substituted acetanilide derivatives are disclosed as analgesic agents. The compounds of the invention are useful in methods for treating a disease or condition in a mammal characterized by pain and/or fever. 123-. (canceled)251. A compound of claim wherein Rand Rtaken together form an optionally substituted imidazole and enantiomers , diastereomers , tautomers , or pharmaceutically acceptable salts thereof.26. A compound selected from the group consisting of:pyridine-2-carboxylic acid (4-hydroxy-phenyl)-amide;5-Methyl-1H-pyrazole-3-carboxylic acid (4-hydroxy-phenyl)-amide; and3H-Imidazole-4-carboxylic acid (4-hydroxy-phenyl)-amide;and enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts thereof.27. A compound of claim 26 , wherein the compound is pyridine-2-carboxylic acid (4-hydroxy-phenyl)-amide and enantiomers claim 26 , diastereomers claim 26 , tautomers claim 26 , or pharmaceutically acceptable salts thereof.28. A compound of claim 26 , wherein the compound is 5-Methyl-1H-pyrazole-3-carboxylic acid (4-hydroxy-phenyl)-amide and enantiomers claim 26 , diastereomers claim 26 , tautomers claim 26 , or pharmaceutically acceptable salts thereof.30. A composition of claim 29 , wherein Rand Rtaken together form an optionally substituted imidazole and enantiomers claim 29 , diastereomers claim 29 , tautomers claim 29 , or pharmaceutically acceptable salts thereof.31. A composition comprising a compound selected from the group consisting of:pyridine-2-carboxylic acid (4-hydroxy-phenyl)-amide;5-Methyl-1H-pyrazole-3-carboxylic acid (4-hydroxy-phenyl)-amide; and3H-Imidazole-4-carboxylic acid (4-hydroxy-phenyl)-amide;and enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts thereof.32. The composition of wherein the compound is pyridine-2-carboxylic acid (4-hydroxy-phenyl)-amide and enantiomers claim 31 , diastereomers claim 31 , tautomers claim 31 , or pharmaceutically acceptable salts thereof.33. The composition of ...

Подробнее
09-05-2013 дата публикации

NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF

Номер: US20130116430A1
Принадлежит: FUJIFILM Corporation

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein Rrepresents a halogen atom; Rrepresents a Calkyl group, a Calkenyl group, a Calkynyl group, a Ccycloalkyl group, an aryl group, an ar-Calkyl group or a heterocyclic group, each optionally having at least one substituent; Rrepresents an aryl group or a heterocyclic group each optionally having at least one substituent; and Rand Reach independently represent a hydrogen atom; and Rand Rmay form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof. 2. The nicotinamide derivative or a salt thereof according to claim 1 , wherein the substituent optionally possessed by the Calkyl group claim 1 , Calkenyl group claim 1 , Calkynyl group claim 1 , Ccycloalkyl group claim 1 , aryl group claim 1 , ar-Calkyl group or heterocyclic group claim 1 , represented by R claim 1 , is selected from the following substituent group α claim 1 , wherein{'sub': 1-1', '1-6', '2-6', '2-6', '3-8', '1-6', '1-6', '1-6', '2-6', '2-6', '3-8', '1-6', '1-6', '2-6', '2-6', '1-12', '2-12', '2-12', '3-8', '1-6', '1-6, 'sup': 1', '2', '6', '7', '6', '7', '6', '7', '1', '2', '7', '7', '29', '29, 'the substituent group αconsists of a halogen atom; a cyano group; a nitro group; an oxo group; an optionally protected carboxyl group; an optionally protected hydroxyl group; an optionally protected amino group; a Calkyl group optionally having at least one substituent; a Calkenyl group optionally having at least one substituent; a Calkynyl group optionally having at least one substituent; a Ccycloalkyl group optionally having at least one ...

Подробнее
09-05-2013 дата публикации

PROCESS FOR THE PREPARATION OF 4-CARBONYL)AMINO]-3-FLUOROPHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE, ITS SALTS AND MONOHYDRATE

Номер: US20130116442A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to a process for preparing 4-{4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate. 2. The process of for preparing the monohydrate of the compound of the formula (I) wherein the salt of the compound of the formula (I) is then treated with an aqueous basic solution to precipitate the monohydrate of the compound of the formula (I).3. The process of wherein the monohydrate of the compound of the formula (I) precipitates at a temperature of from 35° C. to 45° C.4. The process of or for preparing of the compound of the formula (I) wherein the monohydrate is dried under reduced pressure until the compound of the formula (I) is formed.5. The process of any of to wherein the solution comprising the solved compound of the formula (I) and what from the salt of the compound of the formula (I) precipitates is the reaction mixture or is a separate solution of the compound of the formula (I) prepared after isolation of the compound of the formula (I) from the reaction mixture.6. The process of any of to wherein the acid is generated in situ in the reaction mixture after the compound of the formula (I) is formed by adding to the reaction mixture a protic substance and an acid precursor.7. The process of wherein the acid is generated in situ in the reaction mixture after the compound of the formula (I) is formed by adding to the reaction mixture an alcohol and an acylchloride.8. The process of wherein the alcohol is ethanol and the acylchloride is acetylchloride.11. The process of or wherein the compound of the formula (II) is used in a solution of a suitable organic solvent which solution is prepared by neutralization the hydrochloric acid salt of the compound of the formula (II) with a base.12. The process of any of to wherein the compound of the formula (II) it is solved in a suitable organic solvent claim 7 , treated with an acid which is generated in situ by ...

Подробнее
16-05-2013 дата публикации

HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF

Номер: US20130121919A1

The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject. 8. A method for screening compounds of Formula (I) , Formula (II) , Formula (III) , or Formula (V) to treat conditions associated with accumulated amyloid-beta peptide deposits , the method comprising:a) administering a HAT Activator compound of Formula (I), Formula (II), Formula (III), or Formula (V) to an animal model of amyloid-beta peptide deposit accumulation; andb) selecting a HAT Activator compound of Formula (I), Formula (II), Formula (III), or Formula (V) that can modulate histone acetylation after administration of the HAT Activator compound in an animal model of amyloid-beta peptide deposit accumulation.9. A method for identifying a histone acetyltransferase (HAT) activator compound of Formula (I) , Formula (II) , Formula (III) , or Formula (V) to treat conditions associated with accumulated amyloid-beta peptide deposits , wherein the method comprises selecting a HAT Activator compound of Formula (I) , Formula (II) , Formula (III) , or Formula (V) having one or more of the following features:{'sub': '50', 'a) the ECof the compound is no more than about 1000 nM;'}b) the histone acetylation activity in vitro targets histone protein H2, H3, and/or H4; andc) the compound penetrates the blood brain barrier; or a combination thereof.10. The method of claim 9 , wherein the compound has a molecular mass less than about 500 Da claim 9 , has a polar surface area less than about 90 Å claim 9 , has less than 8 hydrogen bonds claim 9 , or a combination thereof claim 9 , in order to penetrate the blood brain barrier.12. The method of claim 11 , wherein the subject ...

Подробнее
16-05-2013 дата публикации

METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE

Номер: US20130123505A1
Принадлежит:

A carboxamide can be produced in a high yield by a method for producing a carboxamide, for example, represented by formula (4): 1. A method for producing a carboxamide , the method comprising allowing a carboxylic acid ester , an amine , and a formamide compound corresponding to the amine to react in the presence of a metal alkoxide.3. The method according to claim 2 , wherein the step is a step of performing the reaction in a solvent.4. The method according to claim 3 , wherein the solvent is an alcohol solvent.5. The method according to claim 2 , wherein the metal alkoxide is an alkali metal alkoxide.6. The method according to claim 2 , wherein the step is a step performed under an increased pressure condition.7. The method according to claim 2 , wherein Rin each of formulae (2) claim 2 , (3) and (4) is a hydrogen atom or a C-Calkyl group.8. The method according to claim 2 , wherein Rin formula (1) is a C-Calkyl group.9. The method according to claim 3 , wherein the metal alkoxide is an alkali metal alkoxide.10. The method according to claim 3 , wherein the step is a step performed under an increased pressure condition. The present invention relates to a method for producing a carboxamide.Carboxamides are important compounds as a variety of chemical products such as active ingredients of medicines and pesticides, and electronic materials, and synthetic intermediates thereof (see, for example, WO2004/065374).In WO2004/065374 is disclosed a method in which ethyl 4,5-bis(4-methoxyphenyl)-1,3-oxazole-2-carboxylate, which is a carboxylic acid ester, is allowed to react with formamide in the presence of sodium methoxide, which is a metal alkoxide, to give 4,5-bis(4-methoxyphenyl)-1,3-oxazole-2-carboxamide, which is a carboxamide, in a yield of 71.9% (see Example 2).However, the method is not necessarily satisfactory in the yield of the carboxamide to be obtained.Thus, new methods by which a carboxamide can be produced from a carboxylic acid ester in a high yield have ...

Подробнее
23-05-2013 дата публикации

Fluro substituted Omega-Carboxyaryl Diphenyl Urea for the Treatment and Prevention of Diseases and Conditions

Номер: US20130131122A1
Принадлежит: Bayer HealthCare LLC

A compound of Formula (I): 154-. (canceled)562. A compound claim where the methylamide group is substituted with a hydroxyl group.571. A pharmaceutical composition comprising a compound of claim and a physiologically acceptable carrier.581. A pharmaceutical composition for the treatment of a cancerous cell growth comprising a compound of claim and a physiologically acceptable carrier for treating cancer.605. A compound claim where either urea nitrogen atom of the compound of formula I is substituted with a hydroxyl group.627. A compound claim where the pyridine nitrogen atom is in the n-oxide form and the methylamide functionality is substituted with a hydroxyl group. This application is a continuation application of U.S. application Ser. No. 10/895,985 filed Jul. 22, 2004 which claims the benefit of the filing date of U.S. Provisional Application Ser. No. 60/489,102 filed Jul. 23, 2003 and U.S. Provisional Application Ser. No. 60/540,326 filed Feb. 2, 2004.This invention relates to novel compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating diseases and conditions mediated by abnormal VEGFR, PDGFR, raf, p38, and/or flt-3 kinase signaling, either alone or in combination with anti-cancer agents.Activation of the ras signal transduction pathway indicates a cascade of events that have a profound impact on cellular proliferation, differentiation, and transformation. Raf kinase, a downstream effector of ras, is recognized as a key mediator of these signals from cell surface receptors to the cell nucleus (Lowy, D. R.; Willumsen, B. M. 1993, 62, 851; Bos, J. L. 1989, 49, 4682). It has been shown that inhibiting the effect of active ras by inhibiting the raf kinase signaling pathway by administration of deactivating antibodies to raf kinase or by co-expression of dominant negative raf kinase or dominant negative MEK, the substrate of raf kinase, leads to the reversion of transformed cells to the normal ...

Подробнее
23-05-2013 дата публикации

LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY

Номер: US20130131321A1
Принадлежит: GRAFFINITY PHARMACEUTICALS GMBH

The present invention relates to the use for affinity purification of an antibody or an fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material, the ligand being represented by formula (I) 2. The use of wherein Aris phenylene claim 1 , preferably methoxy-substituted phenylene.3. The use of wherein the C═O and the NH group are bonded to Arin meta position to each other.4. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris attached to the C═O group via a carbon ring atom which is adjacent to a ring heteroatom claim 1 , preferably a nitrogen or oxygen atom.5. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Arcontains two or more nitrogen atoms or one or more nitrogen atoms and an oxygen atom.6. The use of wherein the 5- or 6-membered heterocyclic aromatic ring of Aris N-methyl-substituted pyrazole claim 5 , pyridine claim 5 , isoxazole or oxadiazole.7. The use according to wherein the support material comprises a material selected from carbohydrates or crosslinked carbohydrates claim 1 , preferably agarose claim 1 , cellulose claim 1 , dextran claim 1 , starch claim 1 , alginate and carrageenan claim 1 , Sepharose claim 1 , Sephadex; synthetic polymers claim 1 , preferably polystyrene claim 1 , styrene-divinylbenzene copolymers claim 1 , polyacrylates claim 1 , PEG-Polycacrylate copolymers polymethacrylates claim 1 , polyvinyl alcohol claim 1 , polyamides and perfluorocarbons; inorganic materials claim 1 , preferably glass claim 1 , silica and metal oxides; and composite materials.8. The use according to wherein the protein is an antibody claim 1 , preferably an IgG type antibody claim 1 , or an Fc fusion protein.9. The use of wherein the purification is attained by binding of the ligand of the ligand-substituted matrix to an Fc fragment or domain of the antibody or the fusion protein.10. The use according to wherein the Fc ...

Подробнее
30-05-2013 дата публикации

Inhibitors of kinase activity

Номер: US20130137660A1
Принадлежит: YM Biosciences Australia Pty Ltd

The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLT1, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDR1 and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.

Подробнее
30-05-2013 дата публикации

NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

Номер: US20130137704A1
Автор: Boléa Christelle
Принадлежит: Addex Pharma, SA

The present invention relates to novel compounds of Formula (I), wherein X, X, X, X, Aand Bare defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR4 receptors. 2. A compound according to claim 1 , which can exist as optical isomers claim 1 , wherein said compound is either the racemic mixture or one or both of the individual optical isomers.3. A compound according to claim 1 , wherein said compound is:N-(3-Chloro-4-(pyrimidin-2-yloxy)phenyl)picolinamideor a pharmaceutically acceptable acid or base addition salt thereof,a stereochemically isomeric form thereof and an N-oxide form thereof.4. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to to and a pharmaceutically acceptable carrier and/or excipient.5. A method of treating or preventing a condition in a mammal claim 1 , including a human claim 1 , the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR4 allosteric modulators claim 1 , comprising administering to a mammal in need of such treatment or prevention claim 1 , an effective amount of a compound/composition according to to .6. A method of treating or preventing a condition in a mammal claim 1 , including a human claim 1 , the treatment or prevention of which is affected or facilitated by the neuromodulatory effect of mGluR4 positive allosteric modulators claim 1 , comprising administering to a mammal in need of such treatment or prevention claim 1 , an effective amount of a compound/composition according to to .7. A method useful for treating or preventing central nervous system disorders selected from the group consisting of: addiction claim 1 , tolerance or dependence claim 1 , affective disorders claim 1 , such as depression and anxiety claim 1 , psychiatric ...

Подробнее
06-06-2013 дата публикации

Novel hydroxamates as therapeutic agents

Номер: US20130142758A1
Принадлежит: Pharmacyclics LLC

The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

Подробнее
06-06-2013 дата публикации

PYRIDINE AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE

Номер: US20130143898A1
Принадлежит: Janssen Pharmaceutica N.V.

This invention comprises the novel compounds of formula (I) 2. A compound according to wherein:a) X is CH;{'sup': '1', 'b) Ris hydroxy;'}{'sup': '2', 'sub': 1-6', '1-6, 'c) Ris amino, Calkylcarbonylamino, Calkylsulfonylamino, phthalimidyl, succinimidyl or phenyloxy wherein the phenyl moiety in said phenyloxy group is optionally substituted with a halo substituent; and'}{'sup': '3', 'sub': 1-6', '1-6', '1-6, 'd) Ris phenyl optionally substituted with one or two substituents each independently selected from halo, Calkyl, Calkyloxy and polyhaloCalkyl.'}3. A compound according to wherein:a) X is CH;{'sup': '1', 'b) Ris hydroxy;'}{'sup': '2', 'c) Ris amino; and'}{'sup': '3', 'sub': '1-6', 'd) Ris phenyl optionally substituted with one substituent selected from halo and Calkyloxy.'}5. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in .6. A method of treating a proliferative disease in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.7. A pharmaceutical composition comprising a compound as claimed in and an anti-cancer agent.11. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in .12. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in .13. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in .14. A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in . This invention ...

Подробнее
06-06-2013 дата публикации

TARGETED CORRECTION OF A GENETIC DEFECT IN CANCER THERAPY

Номер: US20130143933A1
Принадлежит: TRT Pharma Inc.

The present document describes a cancer mutation-selective chemosensitizer that comprise compounds for restoring association between mutated keap1 protein and Nrf2 protein, and inhibition of Nrf2 functions. The present document also describes composition of matter containing the compounds, as well as methods of medical treatment for treating diseases such as cancer with the compounds. 3. The mutation-selective chemosensitizer of claim 1 , wherein said compound corrects a Keap1 mutation to restore interaction between a mutated Keap1 protein and said Nrf2 protein.10. A pharmaceutical composition for the inhibition of a Nrf2 protein which comprises a therapeutically effective amount of a compound of formula (I) as defined in claim 1 , in association with a pharmaceutically acceptable carrier.11. A pharmaceutical composition for overcoming drug resistance in cancer chemotherapy and for the inhibition of tumor growth which comprises a therapeutically effective amount of a compound of formula (I) as defined in claim 1 , in association with a pharmaceutically acceptable carrier.12. A method of treating and/or preventing a disease which involves the abnormal activation or expression of a Nrf2 protein comprising administering a therapeutically effective amount of the compound of formula (I) as defined in of .13. A method of treating a cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of formula (I) as defined in of .14. The method of claims 13 , wherein said cancer is chosen from liver cancer claims 13 , lung cancer claims 13 , breast cancer claims 13 , prostate cancer claims 13 , colon cancer claims 13 , neuroblastoma or leukemia. This application claims priority of U.S. provisional patent application U.S. 61/557,646, filed 9 Nov. 2011, the specification of which is hereby incorporated by reference.(a) FieldThe subject matter disclosed generally relates to a mutation-selective chemosensitizer for overcoming ...

Подробнее
13-06-2013 дата публикации

THERAMUTEIN MODULATORS

Номер: US20130150358A1
Автор: Housey Gerard M.
Принадлежит: HMI MEDICAL INNOVATIONS, LLC.

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein. 2. The method of wherein Xis N.3. The method of wherein Xis N.5. The method of wherein Xis N.6. The method of wherein Xis N.8. The method of wherein Xis N.9. The method of wherein Xis N.11. The method of wherein Xis N.12. The method of wherein Xis N.14. The method of wherein Xis N.15. The method of wherein Xis N.18. The method of wherein Xis N.19. The compound of wherein Xis N.21. The method of wherein Xis N.22. The method of wherein Xis N.24. The method of wherein Xis N.25. The method of wherein Xis N.27. The method of wherein Xis N.28. The method of wherein Xis N.30. The method of wherein Xis N.31. The method of wherein Xis N.33. The method of wherein Xis N.34. The method of wherein Xis N.36. The compound of wherein Xis N.37. The compound of wherein Xis N.52. A method for determining whether a substance is an inhibitor or an activator of a theramutein which is capable of eliciting a detectable phenoresponse claim 36 , which comprises:a) incubating a first cell which expresses the theramutein at a substantially constant level with the substance;b) incubating a second cell which expresses a corresponding prototheramutein at a substantially constant level with a known inhibitor or activator of the prototheramutein;c) comparing a phenoresponse of the second cell to the known inhibitor or activator of the prototheramutein to the phenoresponse of the first cell to the substance; andd) determining that the phenoresponse of the first cell is inhibited or activated to at least the same ...

Подробнее
13-06-2013 дата публикации

Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use

Номер: US20130150368A1
Принадлежит: Cytokinetics Inc

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R 2 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X, Z 1 , Z 2 , Z 3 , Z 4 and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Подробнее
13-06-2013 дата публикации

4-PHENOXY-NICOTINAMIDE OR 4-PHENOXY-PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS

Номер: US20130150372A1
Принадлежит: Hoffmann-La Roche Inc.

This invention relates to novel phenyl amide or pyridyl amide derivatives of the formula 2. A compound according to claim 1 , wherein Ais CR claim 1 , Ais CRand Rand Rare independently from each other selected from the group consisting of hydrogen claim 1 , halogen claim 1 , halogen-C-alkyl and C-alkoxy.3. A compound according to claim 1 , wherein Ais CR claim 1 , Ais N claim 1 , and Ris selected from the group consisting of hydrogen claim 1 , halogen claim 1 , halogen-C-alkyl and C-alkoxy.4. A compound according to claim 1 , wherein Rand Rare independently from each other selected from the group consisting of hydrogen claim 1 , halogen and halogen-C-alkyl.5. A compound according to claim 1 , wherein Rand Rtogether are —X—(CRR)— and form part of a ring; wherein X is —NR— claim 1 , Ris selected from the group consisting of hydrogen claim 1 , C-alkyl and C-cycloalkyl claim 1 , Rand Rare independently from each other hydrogen or methyl claim 1 , and n is 2.6. A compound according to claim 1 , wherein Ris selected from the group consisting of hydrogen claim 1 , C-alkyl claim 1 , C-alkoxy claim 1 , N-heterocyclyl and —NRR claim 1 , wherein Rand Rindependently from each other are selected from hydrogen claim 1 , C-alkyl and C-cycloalkyl claim 1 , and Ris hydrogen or methyl.7. A compound according to claim 1 , wherein Bis N or N—O and Bis CR claim 1 , with Rbeing selected from the group consisting of hydrogen claim 1 , halogen and C-alkyl.8. A compound according to claim 1 , wherein Bis N and Bis N.9. A compound according to claim 1 , wherein Rand Rare independently from each other selected from the group consisting of hydrogen claim 1 , halogen and C-alkyl.10. A compound according to claim 1 , wherein at least two of R claim 1 , R claim 1 , R claim 1 , Rand Rare selected from the group consisting of{'sub': 1-7', '2-7', '2-7', '1-7', '1-7', '1-7', '1-7', '1-7', '3-7', '3-7', '1-7', '1-7', '2-7', '2-7', '1-7', '1-7', '1-7', '2-7', '1-7', '2-7', '1-7', '1-7', '1-7', '1-7', ' ...

Подробнее
13-06-2013 дата публикации

1,4-DISUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPTOR

Номер: US20130150412A1
Принадлежит:

The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) including any stereochemically isomeric form thereof, or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic glutamate receptors subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and such compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved. 137-. (canceled)40. The method according to claim 38 , wherein A is pyridinyl substituted with one substituent claim 38 , said substituent is halo or Calkyl.41. The method according to claim 38 , wherein Ris Calkyl.42. The method according to claim 41 , wherein Ris 1-butyl or 3-methyl-1-butyl.43. The method according to claim 38 , wherein Ris Calkyl substituted with Ccycloalkyl.44. The method according to claim 43 , wherein Ris cyclopropylmethyl or 2-(cyclopropyl)-1-ethyl.45. The method according to claim 38 , wherein Ris hydrogen or fluoro.46. The method according to claim 38 , wherein Ris halo.47. The method according to claim 38 , wherein Ris fluoro.48. The method according to claim 38 , wherein n is 1 and Ris halo.49. The method according to claim 38 , wherein n is 2 and Ris halo.50. The method according to claim 38 , wherein the pyridinyl ring represented by A is substituted with chloro or methyl.51. The method according to claim 38 , ...

Подробнее
13-06-2013 дата публикации

RATIONALLY IMPROVED ISONIAZID AND ETHIONAMIDE DERIVATIVES AND ACTIVITY THROUGH SELECTIVE ISOTOPIC SUBSTITUTION

Номер: US20130150415A1
Принадлежит:

The present invention relates to the use of isotopically labeled derivatives of isoniazid, ethionamide and related compounds as effective therapy for the treatment of mycobacterial diseases, including 144-. (canceled)46. The method according to wherein said NHNHgroup is isotopically labeled with two N atoms.47. The method according to wherein said compound contains at least one isotopically labeled atom selected from the group consisting of carbon-13 claim 45 , nitrogen-15 claim 45 , oxygen-17 and oxygen-18 in the exocyclic acyl hydrazide moiety of the compound.49. The method according to wherein said compound has an isotopically labeled carbon-13 claim 45 , oxygen-17 or oxygen-18 atom.50. The method according to wherein said compound has an isotopically labeled carbon-13 atom.51. The method according to wherein said compound has an isotopically labeled oxygen-17 atom.52. The method according to wherein said compound has an isotopically labeled oxygen-18 atom.53. The method according to wherein said compound has an isotopically labeled carbon-13 atom and an isotopically labeled oxygen-18 atom.54. The method according to wherein said compound has an isotopically labeled nitrogen-15 atom.55MycobacteriumMycobacterium tuberculosis.. The method according to wherein said infection is56. The method according to wherein said infection is latent.57. The method according to wherein said infection is active.58. The method according to wherein said infection is miliary.59. The method according to wherein said infection is extrapulmonary.60. The method according to wherein said infection is renal.62. The method according to wherein said compound is administered in pulmonary dosage form.63. The method according to wherein said compound is administered is oral dosage form.64. The method according to wherein said compound is administered in parenteral dosage form. This application claims the benefit of priority of U.S. provisional application Ser. No. 61/127,150, filed May 9, 2008 ...

Подробнее
20-06-2013 дата публикации

TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS

Номер: US20130157996A1
Принадлежит: Amgen Inc.

Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: 3. The compound of or the pharmaceutically-acceptable salt thereof claim 2 , the tautomer thereof claim 2 , the pharmaceutically-acceptable salt of the tautomer claim 2 , or the mixture thereof claim 2 , wherein{'sup': '2', 'Xis selected from CH or N;'}{'sup': 1', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a', 'a, 'sub': 1-6', '1-2', '1-2', '1-6', '1-6', '1-4', '2', '2-6', '2-6', '2', '2', '2', '2', '2', '2', '2', '2-6', '2-6', '2', '2', '1-6', '1-4', '2', '2, 'Ris selected from Calk or a direct-bonded, Calk-linked, CalkO-linked, saturated, partially-saturated or unsaturated 3-, 4-, 5-, 6- or 7-membered monocyclic or 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O and S, but containing no more than one O or S atom, the Calk and ring being substituted by 0, 1, 2 or 3 substituents independently selected from halo, oxo, Calk, Chaloalk, cyano, nitro, —C(═O)R, —C(═O)OR, —C(═O)NRR, —C(═NR)NRR, —OR, —OC(═O)R, —OC(═O)NRR, —OC(═O)N(R)S(═O)R, —OCalkNRR, —OCalkOR, —SR, —S(═O)R, —S(═O)R, —S(═O)NRR, —S(═O)N(R)C(═O)R, —S(═O)N(R)C(═O)OR, —S(═O)N(R)C(═O)NRR, —NRR, —N(R)C(═O)R, —N(R)C(═O)OR, —N(R)C(═O)NRR, —N(R)C(═NR)NRR, —N(R)S(═O)R, —N(R)S(═O)NRR, —NRCalkNRRand —NRCalkOR, wherein the ring is additionally substituted by 0 or 1 ...

Подробнее
20-06-2013 дата публикации

CONJUGATES OF POLYUNSATURATED FATTY ACIDS AND AMINE-CONTAINING COMPOUNDS AND USES THEREOF

Номер: US20130158070A1
Автор: Nassar Taher
Принадлежит:

Novel chemical conjugates derived from unsaturated fatty acids and therapeutically active agents, are disclosed. The chemical conjugates are designed and characterized as COX-2 and/or 5-LOX inhibitors and are useful in the treatment of inflammatory diseases and disorders such as Alzheimer's disease, Parkinson's disease, asthma, osteoarthritis, rheumatoid arthritis, pain, primary dysmenorrhea, Crohn's disease and ulcerative colitis. 140-. (canceled)41. A method for treating dermatitis in a subject in need comprising the step of administering the subject in need docosa-4 ,7 ,10 ,13 ,16 ,19-hexaenoic acid linked to a hydroxyproline , thereby treating dermatitis in the subject.42. A method of synthesizing 1-docosa-4 ,7 ,10 ,13 ,16 ,19-hexaenoyl-4-hydroxy-pyrrolidine-2-carboxylic acid comprising:mixing tetrahydrofurane with decosahexanoic acid;adding triethylcloroformate;adding triethylamine;stirring and filtering;adding a solution of hydroxyproline and NaOH in water;adding strong acid;adding hexane;collecting organic layer; and drying43. The method according to claim 42 , wherein the step of stirring following the addition of the hydroxyproline and NaOH in water solution claim 42 , is for at 12 hours.44. The method according to claim 42 , wherein the step of drying is over anhydrous sulfate.45. A chemical conjugate comprising a first moiety and a second moiety covalently linked therebetween claim 42 , wherein said second moiety is derived from docosa-4 claim 42 ,7 claim 42 ,10 claim 42 ,13 claim 42 ,16 claim 42 ,19-hexaenoic acid claim 42 , and wherein said first moiety is derived from a therapeutically active agent or a derivative thereof claim 42 , each independently having a functional group for forming a covalent bond with said second moiety claim 42 , with the proviso that said first moiety is not hydroxyproline claim 42 , the chemical conjugate being a cyclooxygenase-2 (COX-2) inhibitor.46. The chemical conjugate of claim 45 , being further a 5-lipoxygenase (5-LOX ...

Подробнее
20-06-2013 дата публикации

PROTEASE INHIBITORS

Номер: US20130158261A1
Принадлежит: TaiMed Biologics, Inc.

The present invention provides HIV protease inhibitors of formulas I, IA, IB, Ib or II, or pharmaceutically acceptable salts thereof, wherein Rmay be, for example, 2-pyridyl-CH—, 3-pyridyl-CH—, 4-pyridyl-CH—, a sulfonyl group as described in the formulas herein including benzenesulfonyl or thiophenesulfonyl groups, R—CO)—, Rbeing selected from the group consisting of piperonyl, 2-pyranzinyl (unsubstituted or substituted with H, or an alkyl of 1 to 4 carbon atoms) or a picolylamine group as described herein, wherein R3 may be, for example, a phenyl group or diphenylmethyl group as described herein, and wherein Cx may be, for example, COOH, CONRR, CHOH or CHOR. 2. (canceled)3. The compound of claim 1 , wherein Cx is CHOH or CHOR.6. The compound of claim 1 , wherein Ris (CH)CH— claim 1 , 1-naphthyl-CH— claim 1 , or 2-naphthyl-CH—.8. The compound of claim 7 , wherein Cx is selected from the group consisting of COOH claim 7 , and CONRR.18. The compound of claim 16 , wherein Cx is CONRR.19. The compound of claim 18 , wherein Rand Rare H. This application claims priority to U.S. Provisional Application No. 60/846,084, filed Sep. 21, 2006, the entire contents of which are herein incorporated by reference.Inhibitors of the HIV viral protease are presently considered the most effective drugs against HIV infection. Unfortunately, most current proteases inhibitors are relatively large hydrophobic molecules that possess rather low bioavailability. A high pill burden is therefore required to attain the therapeutic dose in a patient. This is a deterrent, which too often results in patient non-compliance and inadequate treatment results. This situation leads to sub-optimal therapeutic drug concentration that in turns leads to the development of HIV resistant strains. Consequently, there is an urgent need to improve the solubility and bioavailability of proteases inhibitors.A unique class of amino acid based HIV protease inhibitors have been described in international application No ...

Подробнее
27-06-2013 дата публикации

BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Номер: US20130165443A1
Принадлежит:

Compounds of the formula I: 2. The compound of claim 1 , wherein R claim 1 , Rand Rare hydrogen.3. The compound of claim 2 , wherein Ris phenyl substituted at the 4-position with methyl or halo and optionally substituted at the 2-position with halo.4. The compound of claim 2 , wherein Ris 4-methyl-phenyl.5. The compound of claim 2 , wherein Ris pyridin 2-yl substituted with methyl or halo at the 5-position.6. The compound of claim 2 , wherein Ris 5-methyl-pyridin-2-yl.8. The compound of claim 7 , wherein Ris hydrogen.9. The compound of claim 7 , wherein Ris methyl.10. The compound of claim 7 , wherein Ris: Calkyl; Calkyloxy-Calkyl; hydroxy-Calkyl; Calkylsulfanyl-Calkyl; Calkylsulfonyl-Calkyl; amino-Calkyl; N—Calkyl-amino-Calkyl; N claim 7 ,N-di-Calkyl-amino-Calkyl; Ccycloalkyl; optionally substituted phenyl; heteroaryl claim 7 , or heterocyclyl-Calkyl.11. The compound of claim 7 , wherein Ris: Calkyloxy-Calkyl; hydroxy-Calkyl; heteroaryl claim 7 , or heterocyclyl-Calkyl.12. The compound of claim 7 , wherein Ris methoxymethyl.13. The compound of claim 7 , wherein Ris hydroxymethyl.14. The compound of claim 7 , wherein Ris heteroaryl selected from pyridinyl claim 7 , pyrimidinyl claim 7 , or pyrazinyl claim 7 , each of which may be optionally substituted once or twice with methyl.15. The compound of claim 7 , wherein Ris hydroxymethyl claim 7 , methoxymethyl claim 7 , pyrazin-2-yl or 5-methyl-pyrazin-2-yl.16. The compound of claim 7 , wherein Ris Calkyl claim 7 , Ccycloalkyl or Ccycloalkyl-Calkyl.17. The compound of claim 7 , wherein Ris isopropyl claim 7 , isobutyl or tert butyl.18. The compound of claim 1 , wherein said compound is selected from:4-Methyl-thiophene-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;5-Methyl-thiophene-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;Furan-2-carboxylic acid [5-(2-methoxy-1-methyl-ethylcarbamoyl)-4′-methyl-biphenyl-3-yl]-amide;Thiophene-2- ...

Подробнее
27-06-2013 дата публикации

AROMATIC COMPOUNDS WITH SULFUR CONTAINING LIGANDS

Номер: US20130165630A1

Compounds useful as nutritional supplements, antioxidants, heavy metal chelators and/or as intermediates for producing other related compounds with like uses have a formula: 3. The compound of wherein n=2.4. The compound of wherein R═H.5. The compound of wherein n=3.6. The compound of wherein R═H.7. The compound of wherein n=4.8. The compound of wherein R═H.10. The compound of wherein n=2.11. The compound of wherein R═H.12. The compound of wherein n=3.13. The compound of wherein R═H.14. The compound of wherein n=4.15. The compound of wherein R═H. This application is a continuation-in-part of U.S. patent application Ser. No. 13/565,047 filed 2 Aug. 2012, which is a continuation of U.S. patent application Ser. No. 12/731,415 filed on 25 Mar. 2010, the full disclosure of both is incorporated herein by reference.The present invention relates generally to novel aromatic compounds useful as nutritional supplements, antioxidants, heavy metal chelators and/or also as intermediates for producing other useful compounds of this type.Free radicals are unstable oxygen-containing molecules that negatively interact with other molecules in the body, in a process called oxidation. High levels of free radicals and oxidation can lead to oxidative stress. Moderate oxidative stress can trigger apoptosis: a genetically determined process of cell self destruction marked by fragmentation of nuclear DNA. More intensive oxidative stress may cause widespread necrosis or cell death.The body naturally fights oxidation by producing glutathione (GSH). Glutathione is a tripeptide composed of three amino acid residues: glutamic acid, cysteine and glycine. Glutathione is found in all cells in the body, including the bile, the epithial lining fluid of the lungs and in the blood. Glutathione is the smallest intracellular protein thiol molecule in the cells (that is: a molecule containing an —SH or sulfhydryl group). This characteristic emphasizes its potent antioxidant action and supports a multi- ...

Подробнее
04-07-2013 дата публикации

TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS

Номер: US20130171067A1
Принадлежит: Pierre Fabre Medicament SA

The invention relates to a compound having formula (I), compositions containing same and preparation methods thereof. The invention also relates to a complex of the compound having formula (I) with technetium-99m and tricine, the use of this complex as a diagnostic probe, diagnostic compositions containing same and methods for preparing the complex and compositions containing same.

Подробнее
04-07-2013 дата публикации

Cysteine protease inhibitors

Номер: US20130172232A1
Принадлежит: Medivir UK Ltd

Compounds of the formula I wherein R 2a and R 2b are independently H, halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl or C 1 -C 4 alkoxy, or R 2a and R 2b together with the carbon atom to which they are attached form a C 3 -C 6 cycloalkyl; R 3 is a C 5 -C 10 alkyl, optionally substituted with 1-3 substituents independently selected from halo, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy; or R 3 is a C 2 -C 4 alkyl chain with at least 2 chloro or 3 fluoro substituents; or R 3 is C 3 -C 7 cycloalkylmethyl, optionally substituted with 1-3 substituents independently selected from C 1 -C 4 alkyl, halo, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkoxy; R 4 is C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkoxy, C 1 -C 6 alkylamino, C 1 -C 6 dialkylamino or; R 4 is Het or Carbocyclyl, either of which is optionally substituted with 1-3 substituents R 4 is Het, carbocyclyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkoxy or C 1 -C 6 haloalkoxy; n is 1, 2 or 3; for the use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

Подробнее
04-07-2013 дата публикации

Process for Preparing Carbamolypyridone Derivatives and Intermediates

Номер: US20130172551A1
Принадлежит:

The present invention relates to the preparation of carbamoylpyridone derivatives and intermediates. 8. The method of wherein the hydrolyzing reagent is LiOH.10. The method of wherein the Lewis acid is a magnesium halide or a lithium halide.15. The method of wherein the Lewis acid is a magnesium halide or a lithium halide. The present invention relates to the preparation of carbamoylpyridone derivatives and intermediates which are useful as HIV integrase inhibitors.Compounds having HIV integrase inhibitory activity are described in WO 2006/116764 (corresponding to U.S. Ser. No. 11/919386 assigned to Shionogi & Co. Ltd.). The compounds are disclosed as polycyclic carbamoylpyridone deriviatives. Processes for making them are also disclosed. Among the examples of these compounds, the following polycyclic carbamoylpyridone derivatives are included:The processes disclosed for preparing these compounds are quite arduous, involving as many as 14 steps. It would therefore be an advance in the art to find ways of making these compounds with greater efficiency.The present invention provides an improved process for preparing the following compounds:In one aspect, the present invention is a method comprising contacting methyl 3-{[2,2-bis(methyloxy)ethyl]amino}-2-[(methyloxy)acetyl]-2-propenoate (formula I):with an oxalate ester of formula II:in the presence of MOR, where R is alkyl, aryl, or benzyl; and M is an alkali metal cation; to form a pyridinone of formula III:In a second aspect, the present invention method comprising selectively hydrolyzing a pyridinone of formula III:where R is alkyl, aryl, or benzyl with a selective hydrolyzing reagent to form a pyridinone carboxylic acid of formula IV where R is alkyl, aryl, or benzyl:with greater than 90% selectivity.In a third aspect, the present invention is a method comprising contacting a compound of formula VII:with a magnesium or lithium cation and a nucleophilic anion to form a compound of formula VIII:In a fourth aspect, ...

Подробнее
04-07-2013 дата публикации

PHENOL DERIVATIVES AND PHARMACEUTICAL OR COSMETIC USE THEREOF

Номер: US20130172564A1
Принадлежит: GALDERMA RESEARCH & DEVELOPMENT

The use of compounds in the treatment of skin disorders is described. In particular, use of a compound of formula (I): 2. The compound as defined by claim 1 , wherein:{'sub': '1', 'Rrepresents a halogen, a methyl, an ethyl, an isopropyl, a trifluoromethyl, a nitrile, a nitro, a methoxy, an ethoxy, an isopropoxy, a thiomethyl, a thioethyl, or a thioisopropyl group.'}3. The compound as defined by claim 2 , wherein the Rgroup represents a halogen claim 2 , a methoxy claim 2 , an ethoxy claim 2 , a thiomethyl claim 2 , a thioethyl or a trifluoromethyl group.4. The compound as defined by claim 1 , wherein the Rgroup is a hydrogen atom.5. The compound as defined by wherein the Rgroup is a hydrogen atom or a Calkyl group.6. The compound as defined by claim 1 , wherein the compound is selected from the group consisting of:2-[(5-Bromopyridin-3-ylamino)methyl]phenol;2-[(5-Bromopyridin-3-ylamino)methyl]-3-fluorophenol;2-[(5-Bromopyridin-3-ylamino)methyl]-4-fluorophenol;2-[(5-Methylpyridin-3-ylamino)methyl]phenol;2-[(5-Bromopyridin-3-ylamino)methyl]-5-fluorophenol;2-[(5-Bromopyridin-3-ylamino)methyl]-3,5-dichlorophenol;2-[(5-Bromopyridin-3-ylamino)methyl]-4-chlorophenol;2-[(5-Bromopyridin-3-ylamino)methyl]-4,6-difluorophenol;2-[1-(5-Bromopyridin-3-ylamino)propyl]phenol;2-[1-(5-Bromopyridin-3-ylamino)ethyl]-4-fluorophenol;2-[(5-Methoxypyridin-3-ylamino)methyl]phenol;2-[1-(5-Bromopyridin-3-ylamino)ethyl]phenol;2-[(5-Bromopyridin-3-ylamino)methyl]-3,4-difluorophenol;5-(2-Hydroxybenzylamino)nicotinonitrile;2-[(5-Chloropyridin-3-ylamino)methyl]phenol;5-(2-Hydroxybenzylamino)nicotinonitrile;2-[(5-Chloropyridin-3-ylamino)methyl]phenol;2-[1-(5-Bromopyridin-3-ylamino)butyl]phenol;2-[1-(5-Bromopyridin-3-ylamino)pentyl]phenol;2-[(5-Bromo-6-methylpyridin-3-ylamino)methyl]phenol;2-[(5-Bromo-6-methoxypyridin-3-ylamino)methyl]phenol;5-(2-Hydroxybenzylamino)-3-methylpyridine-2-carbonitrile;2-[(6-Methoxy-5-methylpyridin-3-ylamino)methyl]phenol;2-[(6-Chloro-5-methylpyridin-3-ylamino)methyl] ...

Подробнее
04-07-2013 дата публикации

METHODS OF FORMING 4-CHLORO-2-FLUORO-3-SUBSTITUTED-PHENYLBORONIC ACID PINACOL ESTERS AND METHODS OF USING THE SAME

Номер: US20130172565A1
Принадлежит: DOW AGROSCIENCES LLC

Methods include formation of 4-chloro-2-fluoro-3-substituted-phenylboronic acid pinacol esters. The method comprises contacting a 1-chloro-3-fluoro-2-substituted benzene with an alkyl lithium to form a lithiated 1-chloro-3-fluoro-2-substituted benzene. The lithiated 1-chloro-3-fluoro-2-substituted benzene is contacted with an electrophilic boronic acid derivative to form a 4-chloro-2-fluoro-3-substituted-phenylboronate. The 4-chloro-2-fluoro-3-substituted-phenylboronate is reacted with an aqueous base to form a (4-chloro-2-fluoro-3-substituted-phenyl)trihydroxyborate. The (4-chloro-2-fluoro-3-substituted-phenyl)trihydroxyborate is reacted with an acid to form a 4 chloro-2-fluoro-3-substituted-phenylboronic acid. The 4-chloro-2-fluoro-3-substituted-phenylboronic acid is reacted with 2,3-dimethyl-2,3-butanediol to form 4-chloro-2-fluoro-3-substituted-phenylboronic acid pinacol esters. Methods of using 4-chloro-2-fluoro-3-substituted-phenylboronic acid pinacol esters to produce 6-(4-chloro-2-fluoro-3-substituted-phenyl)-4-aminopicolinates are also disclosed. 1. A method of forming a 4-chloro-2-fluoro-3-substituted-phenylboronic acid pinacol ester , comprising:contacting a 1-chloro-3-fluoro-2-substituted benzene with an alkyl lithium to form a lithiated 1-chloro-3-fluoro-2-substituted benzene;contacting the lithiated 1-chloro-3-fluoro-2-substituted benzene with an electrophilic boronic acid derivative to form a 4-chloro-2-fluoro-3-substituted-phenylboronate;reacting the 4-chloro-2-fluoro-3-substituted-phenylboronate with an aqueous base to form a (4-chloro-2-fluoro-3-substituted-phenyl)trihydroxyborate;reacting the (4-chloro-2-fluoro-3-substituted-phenyl)trihydroxyborate with an acid to form a 4-chloro-2-fluoro-3-substituted-phenylboronic acid; andreacting the 4-chloro-2-fluoro-3-substituted-phenylboronic acid with 2,3-dimethyl-2,3-butanediol.2. The method of claim 1 , reacting the 4-chloro-2-fluoro-3-substituted-phenylboronic acid with 2 claim 1 ,3-dimethyl-2 claim 1 , ...

Подробнее
04-07-2013 дата публикации

METHODS OF PRODUCING METHYL 4-AMINO-3-CHLORO-6-(4-CHLORO-2-FLUORO-3-METHOXYPHENYL)PYRIDINE-2-CARBOXYLATE

Номер: US20130172566A1
Принадлежит: DOW AGROSCIENCES LLC

Methods of producing methyl 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylate. One method comprises adding methyl isobutyl ketone to an aqueous solution comprising 4-chloro-2-fluoro-3-methoxyphenyl-boronic acid to form an organic phase comprising the 4-chloro-2-fluoro-3-methoxyphenylboronic acid and an aqueous phase. The organic phase and the aqueous phase are separated. The 4-chloro-2-fluoro-3-methoxyphenylboronic acid is reacted with methyl 4-(acetylamino)-3,6-dichloropyridine-2-carboxylate in methyl isobutyl ketone to produce methyl 4-(acetylamino)-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylate, which is deacetylated to produce methyl 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylate. 1. A method of producing methyl 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxy-phenyl)pyridine-2-carboxylate , comprising:adding methyl isobutyl ketone to an aqueous solution comprising 4-chloro-2-fluoro-3-methoxy-phenylboronic acid to form an organic phase comprising the 4-chloro-2-fluoro-3-methoxy-phenylboronic acid and an aqueous phase;separating the organic phase comprising the 4-chloro-2-fluoro-3-methoxyphenylboronic acid from the aqueous phase;reacting the 4-chloro-2-fluoro-3-methoxyphenylboronic acid with methyl 4-(acetylamino)-3,6-dichloropyridine-2-carboxylate in methyl isobutyl ketone to produce methyl 4-(acetylamino)-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylate; anddeacetylating the methyl 4-(acetylamino)-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylate to produce methyl 4-amino-3-chloro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylate.2. The method of claim 1 , wherein adding methyl isobutyl ketone to an aqueous solution comprising 4-chloro-2-fluoro-3-methoxyphenylboronic acid comprises forming the organic phase comprising methyl isobutyl ketone and the 4-chloro-2-fluoro-3-methoxyphenylboronic acid and the aqueous phase comprising water and ...

Подробнее
18-07-2013 дата публикации

Adamantyl diamide derivatives and uses of same

Номер: US20130184277A1
Принадлежит: H Lundbeck AS

The present invention provides adamantyl diamide derivatives of formula (I): wherein R 1 and R 2 are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same.

Подробнее
18-07-2013 дата публикации

Novel Phenylamino Isonicotinamide Compounds

Номер: US20130184314A1
Принадлежит: Merck Patent GmBH

The invention provides novel compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. 113-. (canceled)15. A method for treating hyperproliferative diseases related to the hyperactivity of MEK as well as diseases modulated by the MEK cascade in mammals , comprising administering to a subject a compound according to in which radicals not designated in greater detail have the meaning indicated for the Formula (I) according to but in which:in Subformula IAX is NH,{'sup': '1', 'Ris Hal, methyl or ethyl,'}{'sup': '2', 'Ris hydrogen, Hal, methoxy or acetylene,'}{'sup': '3', 'Ris hydrogen or Hal,'}{'sup': '4', 'Ris hydrogen or Hal,'}{'sup': 5', '6, 'R, Rare OH,'}Hal is F, Cl, Br or I,in Subformula IBX is NH,{'sup': '1', 'Ris Hal,'}{'sup': '2', 'Ris hydrogen or Hal,'}{'sup': '3', 'Ris hydrogen or Hal,'}{'sup': '4', 'Ris hydrogen or Hal,'}{'sup': 5', '6, 'R, Rare OH,'}Hal is F, Cl, Br or I,in Subformula ICX is NH,{'sup': '1', 'Ris F, Cl, methyl or ethyl,'}{'sup': '2', 'Ris hydrogen, I, Br, methoxy or acetylene,'}{'sup': '3', 'Ris hydrogen or Hal,'}{'sup': '4', 'Ris hydrogen or Hal,'}{'sup': 5', '6, 'R, Rare OH,'}Hal is F, Cl, Br or I,in Subformula IDX is NH,{'sup': '1', 'Ris F, Cl, methyl or ethyl,'}{'sup': '2', 'Ris hydrogen, I, Br, methoxy or acetylene,'}{'sup': '3', 'Ris hydrogen or F,'}{'sup': '4', 'Ris hydrogen or Cl'}{'sup': 5', '6, 'R, Rare OH,'}in Subformula IEX is NH,{'sup': '1', 'Ris F or Cl,'}{'sup': '2', 'Ris I or Br,'}{'sup': '3', 'Ris hydrogen or F,'}{'sup': '4', 'Ris hydrogen or Cl'}{'sup': 5', '6, 'R, Rare OH,'}in Subformula IFX is NH,{'sup': '1', 'Ris F or Cl,'}{'sup': '2', 'Ris I or Br,'}{'sup': '3', 'Ris hydrogen or F,'}{'sup': '4', 'Ris hydrogen or Cl,'}{'sup': 5', '6, 'R, Rare OH,'}in Subformula IGX is NH,{'sup': '1', 'Ris F or Cl,'}{'sup': '2', 'Ris I or Br,'}{'sup': '3', 'Ris hydrogen,'}{'sup': '4', 'Ris hydrogen,'}{'sup': 5', '6, 'R, Rare OH,'}and in ...

Подробнее
25-07-2013 дата публикации

SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

Номер: US20130190316A1
Принадлежит:

Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation. 3. A compound according to claim 2 , or a tautomer or pharmaceutically acceptable salt thereof claim 2 , wherein Rand Rtogether form oxo.4. A compound according to wherein Rand Rare independently absent or selected from the group consisting of hydrogen claim 2 , R claim 2 , OR claim 2 , O(CH)OR claim 2 , O(CH)NRR claim 2 , OC(O)R claim 2 , COR claim 2 , CONRR claim 2 , and C(O)R claim 2 , where z is 1 claim 2 , 2 claim 2 , or 3.5. A compound according to claim 2 , wherein Tis N; Rand Rare H; Ris absent; and Ris Calkoxy claim 2 , haloCalkoxy claim 2 , and O(CH)Calkyl.6. A compound according to claim 2 , wherein Tis N; Rand Rare H; Ris absent; and Ris selected from hydroxy and Calkoxy.7. A compound according to claim 2 , wherein Tis N; Rand Rare H; Ris absent; and Ris selected from Calkyl and Calkoxy.8. A compound according to claim 5 , wherein Q is selected from the group consisting of an imidazopyridinyl group claim 5 , a pyrrolopyridinyl group claim 5 , a pyrazolopyridinyl group claim 5 , a triazolopyridinyl group claim 5 , a pyrazolopyrazinyl group claim 5 , a pyridinyl group claim 5 , a pyrazinyl group claim 5 , an oxazolyl group claim 5 , an imidazolyl group claim 5 , a triazolyl group claim 5 , a tetrazolyl group claim 5 , a pyrazolyl group claim 5 , a quinolinyl group claim 5 , an isoquinolinyl group claim 5 , an indazolyl group claim 5 , a benzooxazolyl group claim 5 , a naphthyridinyl group claim 5 , and a quinoxalinyl group; and wherein Q is optionally substituted with one to three R.10. A compound according to claim 2 , wherein Tis N; R claim 2 , R claim 2 , and Rare H; and Ris absent.11. A compound ...

Подробнее
25-07-2013 дата публикации

APOPTOSIS PROMOTERS

Номер: US20130190488A1
Принадлежит: ABBOTT LABORATORIES

Disclosed are compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases during which occurs expression one or more than one of an anti-apoptotic protein family member. 19-. (canceled)10. A compound , or a therapeutically acceptable salt thereof , wherein the compound is selected from the group consisting of:N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(5,6-dihydro-1(4H)-pyrimidin-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(2,4-dimenthyl-4,5-dihydro-1H-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-methyl-4,5-dihydro-1H-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((4′-chloro(1,1′-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(4,4-dimethyl-4,5-dihydro-1H-imidazol-1-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((2-(4-chlorophenyl)-1-cyclohexen-1-yl)methyl)piperazin-1-yl(benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)oxy)-3-(trifluoromethyl)benzenesulfonamide;N-(4-(4-((2-(4-chlorophenyl)cyclohept-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-(trifluoromethyl)benzenesulfonamide;4-(((1R)-3-(bis(2-methoxyethyl)amino)-1 ...

Подробнее
01-08-2013 дата публикации

Inhibitors and Methods of Inhibiting Bacterial and Viral Pathogens

Номер: US20130195796A1
Принадлежит: SIGA TECHNOLOGIES INC.

Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed. 2. The composition of claim 1 , wherein Ris hydrogen.3. The composition of claim 1 , wherein Ris chloro.4. The composition of claim 1 , wherein Ris hydrogen.5. The composition of claim 1 , wherein Ris trifluoromethyl.6. The composition of claim 1 , wherein Ris amino.7. The composition of claim 1 , wherein Ris methylamino.8. The composition of claim 1 , wherein Ris hydrogen.9. The composition of claim 1 , wherein Ris methoxy.10. The composition of claim 1 , wherein Ris hydrogen.11. The composition of claim 1 , wherein the compound of Formula I is selected from the group consisting of: N-[(4-amino-3-methoxy-phenyl)carbamothioyl]-4-tert-butyl-benzamide; N-[(4-amino-2-chloro-phenyl)carbamothioyl]-4-tert-butyl-benzamide hydrochloride; 4-tert-butyl-N-[[2-chloro-4-(methylamino)phenyl]-carbamothioyl]benzamide hydrochloride; 4-tert-butyl-N-[(2-chloro-5-methyl-phenyl)-carbamothioyl]benzamide; 4-tert-butyl-N-[(2-chloro-6-methyl-phenyl)-carbamothioyl]benzamide; 4-tert-butyl-N-[[2-chloro-3-(trifluoromethyl)phenyl]-carbamothioyl]benzamide; N-[(4-amino-3-methoxy-phenyl)carbamothioyl]-4-tert-butyl-benzamide hydrochloride; 4-tert-butyl-N-[(2-chloro-3-methyl-phenyl)-carbamothioyl]benzamide; 4-tert-butyl-N-[[4-(methylamino)phenyl]-carbamothioyl]benzamide hydrochloride; 4-tert-butyl-N-[[2-chloro-4-(dimethylamino)phenyl]-carbamothioyl]benzamide hydrochloride; 4-tert-butyl-N-[[2-chloro-5-(trifluoromethoxy)phenyl]-carbamothioyl]benzamide; 4-tert-butyl-N-[[4-(3-pyridylamino)phenyl]-carbamothioyl]benzamide hydrochloride; 4-tert-butyl-N-[(2-chlorophenyl)carbamothioyl]-benzamide; 4-tert-butyl-N-(o-tolylcarbamothioyl)-benzamide; 4-tert-butyl-N-[[2-chloro-5-(trifluoromethyl)phenyl]-carbamothioyl]benzamide; N ...

Подробнее
01-08-2013 дата публикации

N-heteroaryl compounds

Номер: US20130196993A1
Принадлежит: Individual

This invention relates to certain N-heteroaryl compounds that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to novel N-heteroaryl compounds and the preparation of said compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

Подробнее
08-08-2013 дата публикации

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Номер: US20130203747A1
Принадлежит: Gilead Sciences, Inc.

Compounds of formula I: 6. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris (C)alkyl claim 1 , —CN claim 1 , halo or (C)haloalkyl.7. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ris —CH.11. A pharmaceutical composition comprising a compound of formula (I) according to any one of to claim 1 , or a pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable carriers.12. A method of treating HIV infection which comprises administering to a host infected by HIV a therapeutically effective amount of a compound of formula (I) according to any one of to claim 1 , or a pharmaceutically acceptable salt thereof. This application claims benefit of U.S. Ser. No. 61/178,551, filed May 15, 2009, and U.S. Ser. No. 61/285,766, filed Dec. 11, 2009, which are herein incorporated by reference.The present invention relates to compounds, compositions and methods for the treatment of human immunodeficiency virus (HIV) infection. In particular, the present invention provides novel inhibitors of the HIV integrase enzyme, pharmaceutical compositions containing such compounds and methods for using these compounds to reduce HIV replication and in the treatment of HIV infection.Acquired immune deficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV), particularly the HIV-1 strain. Most currently approved therapies for HIV infection target the viral reverse transcriptase and protease enzymes. There are also two approved drugs targeting HIV entry and one approved drug targeting the integrase enzyme. Within the reverse transcriptase inhibitor and protease inhibitor classes, resistance of HIV to existing drugs is a problem. Therefore, it is important to discover and develop new antiretroviral compounds.International patent application WO 2007/131350 and United States published patent application US 2006/0106070 describe compounds which are active ...

Подробнее
08-08-2013 дата публикации

COMPOUNDS FOR TREATMENT OF TUMORS BEARING DEREGULATED MYC ONCOPROTEINS

Номер: US20130203822A1
Принадлежит:

Compound of Formula (I): wherein R, Rand R, which are identical or different, are hydrogen atom or Calkyl, and Ris a saturated Clinear, branched or cyclic hydrocarbon radical or a radical of Formula (II) wherein X is S or O, Y is a hydrogen atom or up to 2 halogen atoms, Z is a single bond or a divalent radical being O, S, —CR—, in which R is hydrogen or Calkyl, or other divalent radical with 2-10 carbon atoms and, optionally, O and/or S atoms linked in the form of a chain, wherein—if the radicals contain 2 or more O and/or S atoms—the latter are separated from one another by at least 2 carbon atoms, and it also being possible for 2 adjacent carbon atoms to be linked together by a double bond, and the free valencies of the carbon atoms being saturated by a hydrogen atom and/or Calkyl groups, Ar is an aromatic ring system which has up to two rings and which may be substituted by up to three radicals from the group of fluorine, chlorine, bromine, methoxy, Calkyl, trifluoromethyl and trifluoromethoxy, salts and/or solvates thereof, for use in the treatment of a tumor bearing deregulated MYC oncoproteins, wherein said compound is capable of increasing UTR-dependent expression of at least one MYC gene. 2. Compound according to claim 1 , wherein R claim 1 , R claim 1 , Rand Rare hydrogen atoms.3. Compound according to claim 1 , wherein Ris a methyl group claim 1 , Rand Rare hydrogen atoms claim 1 , and Ris cyclohexyl.4. Compound according to claim 3 , wherein the compound is a solvate with 2-aminoethanol.5. Compound according to claim 1 , wherein Ris a methyl group claim 1 , Rand Rare hydrogen atoms claim 1 , and Ris 2 claim 1 ,4 claim 1 ,4-trimethylpentyl.6. Compound according to claim 5 , wherein the compound is a solvate with 2-aminoethanol.7. Compound according to claim 1 , wherein Ris a methyl group claim 1 , Rand Rare hydrogen atoms claim 1 , and Ris 4-(4-chlorophenoxy)-phenoxy-methyl].8. Compound 1-hydroxypyridine-2-thione for use in the treatment of a tumor ...

Подробнее
08-08-2013 дата публикации

AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME

Номер: US20130203987A1
Принадлежит: Rigel Pharmaceuticals, Inc.

Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure 2. The compound according to claim 1 , wherein D claim 1 , Dand Dare independently CH or C substituted by one of the w R.3. The compound according to claim 1 , wherein x is 0.4. The compound according to claim 1 , wherein the ring system denoted by “B” is arylene or heteroarylene.6. The compound according to claim 1 , wherein J is —NR— or —NRC(O)—.7. The compound according to claim 1 , wherein J is —C(O)NR— or —C(O)—.9. The compound according to claim 1 , wherein Rand Rtogether with the nitrogen to which they are bound form Hca.10. The compound according to wherein Ris -Cak. This application is a continuation of U.S. patent application Ser. No. 13/194,810, filed Jul. 29, 2011, which in turn claims the benefit of the earlier filing date of U.S. Provisional Patent Application Ser. No. 61/368,928, filed Jul. 29, 2010, each of which is hereby incorporated herein by reference in its entirety.1. FieldThis disclosure relates generally to compounds, pharmaceutical compositions and methods of use of the compounds and compositions containing them. This disclosure relates more particularly to certain substituted pyridine compounds and pharmaceutical compositions thereof, and to methods of treating and preventing metabolic disorders such as type II diabetes, atherosclerosis and cardiovascular disease using certain substituted pyridine compounds.2. Technical BackgroundThe kinase 5′-AMP-activated protein kinase (AMPK) is well established as an important sensor and regulator of cellular energy homeostasis. Being a multi-substrate enzyme, AMPK regulates a variety of metabolic processes, such as glucose transport, glycolysis and lipid metabolism. It acts as a sensor of cellular energy homeostasis and is activated in response to certain hormones and muscle contraction as well as to intracellular metabolic stress signals such as ...

Подробнее
15-08-2013 дата публикации

CANNABIDINOID DERIVATIVES

Номер: US20130209483A1
Автор: McAllister Sean D.
Принадлежит: Sutter West Bay Hospitals

The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer. 2. The compound of claim 1 , wherein Ris selected from the group consisting of methyl claim 1 , ethyl claim 1 , n-propyl claim 1 , n-butyl claim 1 , n-pentyl claim 1 , n-hexyl claim 1 , n-heptyl claim 1 , isopropyl claim 1 , sec-butyl claim 1 , (1-methyl)butyl claim 1 , (1-methyl)pentyl claim 1 , (1-methyl)hexyl claim 1 , (1-methyl)heptyl claim 1 , (1 claim 1 ,1-dimethyl)propyl claim 1 , (1 claim 1 ,1-dimethyl)butyl claim 1 , (1 claim 1 ,1-dimethyl)pentyl claim 1 , (1 claim 1 ,1-dimethyl)hexyl claim 1 , (1 claim 1 ,1-dimethyl)heptyl claim 1 , (1 claim 1 ,2-dimethyl)propyl claim 1 , (1 claim 1 ,2-dimethyl)butyl claim 1 , (1 claim 1 ,2-dimethyl)pentyl claim 1 , (1 claim 1 ,2-dimethyl)hexyl claim 1 , (1 claim 1 ,2-dimethyl)heptyl claim 1 , (1 claim 1 ,3-dimethyl)butyl claim 1 , (1 claim 1 ,3-dimethyl)pentyl claim 1 , (1 claim 1 ,3-dimethyl)hexyl claim 1 , (1 claim 1 ,3-dimethyl)heptyl claim 1 , (1 claim 1 ,4-dimethyl)pentyl claim 1 , (1 claim 1 ,4-dimethyl)hexyl claim 1 , (1 claim 1 ,4-dimethyl)heptyl claim 1 , (1 claim 1 ,5-dimethyl)hexyl claim 1 , (1 claim 1 ,5-dimethyl)heptyl claim 1 , (1 claim 1 ,6-dimethyl)heptyl claim 1 , (1 claim 1 ,2-diethyl)butyl claim 1 , (1 claim 1 ,2-diethyl)pentyl claim 1 , (1 claim 1 ,2-diethyl)hexyl claim 1 , (1 claim 1 ,2-diethyl)heptyl claim 1 , (1 claim 1 ,2-diethyl)pentyl claim 1 , (1 claim 1 ,3-diethyl)pentyl claim 1 , (1 claim 1 ,3-diethyl)hexyl claim 1 , (1 claim 1 ,3-diethyl)heptyl claim 1 , (1 claim 1 ,4-diethyl)pentyl claim 1 , (1 claim 1 ,4-diethyl)hexyl claim 1 , (1 claim 1 ,4-diethyl)heptyl claim 1 , (1 claim 1 ,5-diethyl)hexyl claim 1 , (1 claim 1 ,5-diethyl)heptyl claim 1 , (1 claim 1 ,6-diethyl)heptyl claim 1 , (1 claim 1 ,2 claim 1 ,3-trimethyl)butyl claim 1 , (1 claim 1 ,1 claim 1 ,2-trimethyl)butyl claim 1 , (1 claim 1 ,1 claim 1 ,3-trimethyl) ...

Подробнее
15-08-2013 дата публикации

PHOTOLABILE CAGED TRANSITION METAL COMPLEXES AND METHODS OF USING THE SAME

Номер: US20130210793A1
Принадлежит: Duke University

The present invention provides compounds of Formula I: 2. The compound of claim 1 , wherein Z is absent.3. The compound of claim 1 , wherein Z is a transition metal.4. The compound of claim 1 , wherein Z is a transition metal selected from the group consisting of copper claim 1 , platinum claim 1 , iron and zinc.5. The compound of claim 1 , wherein at least one adjacent pair of Rand Rtogether form a heteroaryl selected from the group consisting of pyrimidine claim 1 , thiazole claim 1 , thiophene claim 1 , isoquinoline claim 1 , imidazole claim 1 , and pyrroline.6. The compound of claim 1 , wherein Ris selected from the group consisting of: H claim 1 , alkyl claim 1 , alkoxy claim 1 , halo claim 1 , and sulfonate.7. The compound of claim 1 , wherein Ris selected from the group consisting of: H claim 1 , alkyl claim 1 , alkoxy claim 1 , halo claim 1 , and sulfonate.8. The compound of claim 1 , wherein Ris selected from the group consisting of: H claim 1 , alkyl claim 1 , alkoxy claim 1 , halo claim 1 , and sulfonate.9. The compound of claim 1 , wherein Ris selected from the group consisting of: H claim 1 , alkyl claim 1 , alkoxy claim 1 , halo claim 1 , and sulfonate.10. The compound of claim 1 , wherein Rand Rtogether form oxo.11. The compound of claim 1 , wherein each Ris independently selected from the group consisting of: H claim 1 , alkyl claim 1 , alkoxy claim 1 , halo claim 1 , and sulfonate.12. The compound of claim 1 , wherein each Ris independently selected from the group consisting of: H claim 1 , alkyl claim 1 , alkoxy claim 1 , halo claim 1 , and sulfonate.13. The compound of claim 1 , wherein each Ris independently selected from the group consisting of: H claim 1 , alkyl claim 1 , alkoxy claim 1 , and halo.14. The compound of claim 1 , wherein each Ris independently selected from the group consisting of: H claim 1 , alkyl claim 1 , alkoxy claim 1 , and halo.16. A composition comprising a compound of in a pharmaceutically acceptable carrier.1718-. ( ...

Подробнее
15-08-2013 дата публикации

SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF

Номер: US20130210795A1
Принадлежит: Bayer Intellectual Property GmbH

The present application relates to novel substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders. 6. (canceled)7. (canceled)8. (canceled)9. A pharmaceutical composition claim 1 , comprising a compound of and an inert nontoxic pharmaceutically suitable auxiliary.10. The pharmaceutical composition of claim 9 , further comprising at least one active ingredient selected from the group consisting of a lipid metabolism-modifying active ingredient claim 9 , an antidiabetic claim 9 , a antihypertensive drug claim 9 , and an antithrombotic drug.11. (canceled)12. A method for the treatment and/or prophylaxis of hypertension claim 1 , coronary heart disease claim 1 , acute coronary syndrome claim 1 , angina pectoris claim 1 , heart failure claim 1 , myocardial infarction claim 1 , atrial fibrillation claim 1 , diabetes claim 1 , metabolic syndrome and dyslipidemias comprising administering an effective amount of at least one compound of to a human or animal in need thereof.13. A method for the treatment and/or prophylaxis of hypertension claim 9 , coronary heart disease claim 9 , acute coronary syndrome claim 9 , angina pectoris claim 9 , heart failure claim 9 , myocardial infarction claim 9 , atrial fibrillation claim 9 , diabetes claim 9 , metabolic syndrome and dyslipidemias comprising administering an effective amount of at least one pharmaceutical composition of to a human or animal in need thereof. The present application relates to novel substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders. ...

Подробнее
15-08-2013 дата публикации

SORAFENIB DIMETHYL SULPHOXIDE SOLVATE

Номер: US20130210865A1
Принадлежит: RANBAXY LABORATORIES LIMITED

The present invention provides dimethyl sulphoxide solvate of 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N-methylpyridine-2-carboxamide, process for its preparation, pharmaceutical composition comprising it and its use for the treatment of cancer. The present invention also provides a novel HPLC method for the identification, quantification and isolation of related substances of sorafenib. 2. Sorafenib dimethyl sulphoxide solvate according to further characterized by X-ray diffraction peaks at d-spacing 5.36 claim 1 , 4.47 claim 1 , 4.44 claim 1 , 3.26 and 3.14 Å.3. Sorafenib dimethyl sulphoxide solvate of Formula III characterized by X-ray diffraction pattern as depicted in .4. Sorafenib dimethyl sulphoxide solvate of Formula III characterized by DSC thermogram having endotherms at about 123.69° C. and about 202.54° C.5. Sorafenib dimethyl sulphoxide solvate of Formula III characterized by DSC thermogram as depicted in .6. Sorafenib dimethyl sulphoxide solvate of Formula III characterized by X-ray diffraction pattern as depicted in and DSC thermogram as depicted in .7. Sorafenib dimethyl sulphoxide solvate of Formula III characterized by TGA as depicted in .8. Sorafenib dimethyl sulphoxide solvate of Formula III characterized by IR spectrum as depicted in .9. Sorafenib dimethyl sulphoxide solvate of Formula III having purity greater than 99% by HPLC.11. The process according to claim 10 , wherein Sorafenib free base of Formula I is contacted with dimethyl sulphoxide at a temperature of about 15° C. to the reflux temperature of dimethyl sulphoxide.13. The process according to claim 12 , wherein the solvent is selected from the group consisting of water claim 12 , chlorinated hydrocarbons claim 12 , alcohols claim 12 , ketones claim 12 , alkyl acetates claim 12 , ethers and mixtures thereof.14. The process according to claim 12 , wherein sorafenib dimethyl sulphoxide solvate of Formula III is contacted with a solvent at a temperature of about −5° C. ...

Подробнее
15-08-2013 дата публикации

Process for the Preparation of 1-Hydroxy-6-Substituted Pyridones

Номер: US20130211093A1
Принадлежит: ARCH CHEMICALS, INC.

Disclosed herein is a cost effective and environmentally friendly process to prepare 1-hydroxy-6-substituted pyridones from 2,6-dichloropyridine. The process includes the steps of (a) reacting 2,6-dichloropyridine with hydrogen peroxide in the presence of trifluoroacetic acid at a first temperature to produce a first intermediate containing (1) trifluoroacetic acid and (2) 2,6-dichloropyridine N-oxide and/or salts thereof; (b) adding sulfuric acid to the first intermediate to provide a second intermediate; (c) removing trifluoroacetic acid from the second intermediate to provide a composition containing 2,6-dichloropyridine N-oxide and/or salts thereof which is essentially free of trifluoroacetic acid; (d) reacting 2,6-dichloropyridine N-oxide and/or salts thereof from step (c) with RXH and a base wherein each R is independently a substituted or unsubstituted hydrocarbyl group having between 1 and 20 carbon atoms, X is oxygen or sulfur, to produce a corresponding 2,6-disubstituted-pyridine N-oxide; and (e) heating the disubstituted compound thereby producing the 1-hydroxy-6-substituted pyridone. 1. A process for separating (1) an acid catalyst and (2) 2 ,6-dichloropyridine-N-oxide and/or salts thereof from a composition containing (1) the acid catalyst and (2) 2 ,6-dichloropyridine-N-oxide and/or salts thereof , the process comprisingadding an acid having a pKa number lower than the pKa number of the acid catalyst to the a composition containing (1) an acid catalyst and (2) 2,6-dichloropyridine-N oxide and/or salts thereof; andremoving the acid catalyst.3. A process as defined in claim 2 , wherein the acid catalyst comprises trifluoroacetic acid.4. A process as defined in claim 2 , wherein the acid comprises sulfuric acid.5. A process for separating (1) trifluoroacetic acid and (2) 2 claim 2 ,6-dichloropyridine-N-oxide and/or salts thereof from a composition containing (1) trifluoroacetic acid and (2) 2 claim 2 ,6-dichloropyridine-N-oxide and/or salts thereof claim ...

Подробнее
29-08-2013 дата публикации

Pyridine Derivative and Medicinal Agent

Номер: US20130225548A1
Принадлежит: NIPPON SHINYAKU CO., LTD.

A main object of the present invention is to provide a novel pyridine derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof. 2. The pyridine derivative or pharmaceutiealiy acceptable salt thereof according to claim 1 , wherein aryl or heteroaryl represented by R is phenyl claim 1 , pyridyl claim 1 , pyrimidinyl claim 1 , benzimidazolyl claim 1 , indazolyl claim 1 , or isoquinolyl.3. The pyridine derivative or pharmaceutically acceptable salt thereof according to claim 1 , wherein Rcycloalkyl which may be substituted with hydroxy or hydroxyalkyl claim 1 , or a 4- to 7-membered saturated heterocyclic group claim 1 , which has one or two heteroatoms claim 1 , and is substituted with one or two substituents selected from the group consisting of cyano claim 1 , hydroxy claim 1 , oxo claim 1 , halogen claim 1 , alkylarbonyl claim 1 , amino claim 1 , monoalkylamino claim 1 , dialkylamino claim 1 , alkylcarbonylamino claim 1 , carbamoylamino claim 1 , monoalkylaminocarbonylamino claim 1 , alkyl claim 1 , hydroxyalkyl claim 1 , hydroxycarbonylalkyl claim 1 , carbamoylalkyl claim 1 , monoalkylaminocarbonylalkyl claim 1 , dialkylaminocarbonylalkyl claim 1 , hydroxy carbonyl claim 1 , carbamoyl claim 1 , monoalkylaminocarbonyl claim 1 , dialkylaminocarbonyl claim 1 , aminothiocarbonyl claim 1 , alkylsulfonyl and aryl which may be substituted with halogen.5. A pharmaceutical composition comprising the pyridine derivative or pharmaceutiealiy acceptable salt thereof according to as an active ingredient.6. A Syk tyrosine kinase inhibitor comprising the pyridine derivative or pharmaceutiealiy acceptable salt thereof according to as an active ingredient.7. A preventive agent or a therapeutic agent for an allergic disease claim 1 , an autoimmune disease claim 1 , or a malignant tumor claim 1 , comprising as an active ingredient the pyridine derivative or pharmaceutiealiy acceptable salt thereof according to .8. The preventive agent ...

Подробнее
29-08-2013 дата публикации

5-Alkynyl Pyridine

Номер: US20130225567A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

5-alkynyl-pyridine of general formula (I) 2. A compound according to claim 1 , wherein Ris —CHor —CH—CH.3. A compound according to claim 1 , wherein Rand Rare independently selected from —H claim 1 , —CH claim 1 , —CH—CH. —CH—(CH) claim 1 , and —(CH)—CH.4. A compound according to claim 1 , wherein Ris selected from —H claim 1 , —Cl claim 1 , —F claim 1 , —CF claim 1 , —OCH claim 1 , and —CH.5. A compound according to claim 1 , wherein Ris selected from —Caryl claim 1 , and 5-14 membered heteroaryl claim 1 , each of which groups can be optionally and independently substituted with one or more claim 1 , independently selected claim 1 , R claim 1 , or Ris selected from —Ccycloalkenyl claim 1 , and 5-14 membered aromatic ring system claim 1 , each of which groups can be optionally and independently substituted with one or more claim 1 , independently selected R claim 1 , or Ris —CH-phenyl claim 1 , which phenyl can be optionally substituted with —O—Calkyl.6. A compound according to claim 1 , wherein Ris selected from —Caryl claim 1 , 5-14 membered heteroaryl claim 1 , each of which groups can be optionally and independently substituted with one or more claim 1 , independently selected claim 1 , R claim 1 , or Ris selected from 5-14 membered aromatic ring system claim 1 , which groups can be optionally and independently substituted with one or more claim 1 , independently selected claim 1 , R claim 1 , wherein Rand Rare as defined in .8. A compound according to claim 1 , wherein Ris selected from —H claim 1 , —Caryl and 5-14 membered heteroaryl claim 1 , each of which group is optionally and independently substituted with one or more claim 1 , independently selected claim 1 , R claim 1 ,{'sup': 4', '7a, 'sub': 1-6', '5-7, 'or Ris selected from —Calkyl, 5-14 membered aromatic ring system and —Ccycloalkyl, each of which group is optionally and independently substituted with one or more, independently selected, R,'}{'sup': 4', '8', '9, 'or Ris selected from —N(R,R).'}9. A ...

Подробнее
29-08-2013 дата публикации

ANTICANCER COMPOUNDS AND PREPARATION METHODS THEREOF

Номер: US20130225641A1
Автор: Zhang Nan, Zhong Rong
Принадлежит:

Two new compounds with anticancer effects of N-[4-chloro-3-(trifluoromethyl)phenyl]-[4-(N-methyl-formamide)(4-pyridyloxy)phenyl]-thiourea and N-[4-chloro-3-(trifluoromethyl)phenyl]-[4-(N-methyl-formamide)(4-pyridylthio)phenyl]-thiourea, and salts thereof are disclosed. Preparation methods of the two new compounds and pharmaceutical compositions containing the new compounds are further disclosed. Experimental studies show that the two new compounds can effectively inhibit the activity of Raf and VEGFR protein kinase, widely inhibit growth of various types of human tumor cell lines and further induce apoptosis of tumor cells. Human tumor heterograft model investigation proves that the two new compounds are effective antineoplastic agents, and can sharply inhibit growth of human liver cancer cells, lung cancer cells and intestinal cancer cells in vivo. Furthermore, the anticancer effects of the compounds are much better than that of Sorafenib. 2. A method for preparing the compound of claim 1 , the method comprising:(1) adding dimethyl formamide dropwise to a solution of pyridine-2-carboxylic acid in thionyl chloride at 40° C., stirring, then heating to 72° C., and stirring overnight; and cooling to room temperature after the reaction is completed, removing thionyl chloride under reduced pressure, adding toluene, evaporating to dryness under reduced pressure, and then adding toluene again, to obtain a solution of 4-chloropyridyl-2-carbonyl chloride in toluene;(2) adding the solution of 4-chloropyridyl-2-carbonyl chloride in toluene dropwise to an aqueous methylamine solution cooled to −5° C., and stirring when the temperature is below 20° C.; and then adding ethyl acetate and water, washing the organic layer with saturated saline, drying it over anhydrous sodium sulfate, and then concentrating to an orange oil, to obtain 4-chloro(2-pyridyl)-N-methylcarboxamide;{'sup': '˜', '(3) Under the protection of nitrogen, dissolving 4-aminophenol in dimethylformamide, then adding ...

Подробнее
05-09-2013 дата публикации

MODIFIED 4-PHENYL-PYRIDINE DERIVATIVES

Номер: US20130231315A1
Принадлежит: HELSINN HEALTHCARE SA

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK) receptor. The compounds have the general formula (I): 110-. (canceled)12) The method of claim 11 , wherein said emesis comprises chemotherapy induced nausea and vomiting (CINV) claim 11 , radiation therapy induced nausea and vomiting (RINV) claim 11 , or post-operative nausea and vomiting (PONV).13) The method of claim 11 , wherein said emesis is induced by moderately or highly emetogenic chemotherapy.14) The method of claim 11 , wherein emesis is acute and delayed emesis induced by moderately or highly emetogenic chemotherapy.15) (canceled)16) The method of claim 11 , wherein said compound or a pharmaceutically acceptable salt thereof claim 11 , is administered by one or more routes selected from the group consisting of rectal claim 11 , buccal claim 11 , sublingual claim 11 , intravenous claim 11 , subcutaneous claim 11 , intradermal claim 11 , transdermal claim 11 , intraperitoneal claim 11 , oral claim 11 , eye drops claim 11 , parenteral and topical administration.17) The method of claim 11 , wherein said compound or a pharmaceutically acceptable salt thereof claim 11 , is intravenously administered at a dosage of from about 10 mg to about 200 mg.18) The method of claim 11 , wherein said emesis is acute and delayed emesis induced by moderately or highly emetogenic chemotherapy claim 11 , further comprising administering a 5-HTantagonist and corticosteroid.19) The method of claim 18 , wherein said 5-HTantagonist is ondansetron claim 18 , palonosetron claim 18 , granisetron or tropisetron claim 18 , or a pharmaceutically acceptable salt thereof.20) The method of claim 11 , further comprising administering 2-(3 claim 11 ,5-bis(trifluoromethyl)phenyl)-N claim 11 ,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide (netupitant).21) The method of claim 11 , wherein the subject is a ...

Подробнее
05-09-2013 дата публикации

Novel Process For The Preparation Of Roflumilast

Номер: US20130231374A1
Принадлежит: NYCOMED GMBH

A composition comprising: roflumilast having a purity of greater than or equal to 99% by weight, and N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight. 121.-. (canceled)22. A composition comprising: roflumilast having a purity of greater than or equal to 99% by weight , and N-(3 ,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight.23. The composition of claim 22 , wherein said roflumilast has a purity of greater than or equal to 99.8% by weight.24. The composition of claim 22 , wherein said N-(3 claim 22 ,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide is present (relative to roflumilast) in an amount greater than zero and less than 0.05% by weight.25. A pharmaceutical composition claim 22 , comprising: roflumilast having a purity of greater than or equal to 99% by weight; N-(3 claim 22 ,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight; and pharmaceutically acceptable auxiliaries and/or excipients.26. The pharmaceutical composition of claim 25 , wherein said roflumilast has a purity of greater than or equal to 99.8% by weight.27. The pharmaceutical composition of claim 25 , wherein said N-(3 claim 25 ,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide is present (relative to roflumilast) in an amount greater than zero and less than 0.05% by weight.28. A pharmaceutical dosage form claim 25 , comprising: roflumilast having a purity of greater than or equal to 99% by weight; N-(3 claim 25 ,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-hydroxybenzamide present (relative to roflumilast) in an amount greater than zero and less than 0.1% by weight; and pharmaceutically acceptable auxiliaries and/or excipients.29. The pharmaceutical ...

Подробнее
05-09-2013 дата публикации

COMPOUNDS FOR PRODUCING SUBSTITUTED SULFOXIDES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF

Номер: US20130231486A1
Принадлежит: Matrix Laboratories Limited

Disclosed herein are novel compounds which are useful as intermediates for producing substituted sulfoxide compounds and a process for producing the same. Further disclosed is a process for producing the substituted sulfoxide compounds used as pharmacologically active agents, employing the novel intermediates of the present invention. 8. The process according to claim 7 , wherein the alcohol of the formula HOR′ is selected from trifluoroethanol claim 7 , 3-methoxypropanol or methanol.9. The process according to claim 7 , wherein the base used is selected from sodium hydroxide claim 7 , potassium hydroxide claim 7 , sodium hydride claim 7 , calcium hydroxide claim 7 , barium hydroxide claim 7 , magnesium hydroxide claim 7 , sodium carbonate claim 7 , potassium carbonate claim 7 , cesium carbonate claim 7 , sodium methoxide claim 7 , sodium tertiary butoxide or potassium tertiary butoxide.10. The process according to claim 7 , wherein the solvent used is selected from dimethylsulfoxide claim 7 , dimethylformamide claim 7 , dimethyl acetate claim 7 , N-methylpyrrolidone claim 7 , methanol claim 7 , ethanol claim 7 , dioxane claim 7 , toluene claim 7 , xylene claim 7 , tetrahydrofuran claim 7 , dichloromethane acetonitrile claim 7 , sulpholane or mixtures thereof. This patent application is a divisional of U.S. patent application Ser. No. 13/121,387, which is the U.S. national stage of international application no. PCT/IN2009/000526, filed Sep. 29, 2009, which claims priority to Indian patent application no. 02/CHE/009, filed Jan. 1, 2009 and to Indian patent application no. 2366/CHE/2008, filed Sep. 26, 2008. The foregoing patent applications are incorporated herein by reference.The present invention relates to novel compounds, process for producing the same and use thereof in the large scale production of substituted sulfoxides, their enantiomers or pharmaceutically acceptable salts thereof.Substituted sulfoxide compounds or their enantiomers (viz., Omeprazole, ...

Подробнее
12-09-2013 дата публикации

COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR

Номер: US20130237531A1
Принадлежит:

Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. 2. The compound of claim 1 , wherein Ris hydrogen.3. The compound of claim 2 , wherein Ris halogen.4. The compound of claim 2 , wherein Ris optionally substituted phenyl.5. The compound of claim 2 , wherein Ris phenyl optionally substituted with one or more halogen substituents.6. The compound of claim 1 , wherein Ris phenyl optionally substituted with one or more fluoro substituents.7. The compound of claim 6 , wherein Ris phenyl substituted with two fluoro substituents.8. The compound of claim 1 , wherein each Ris independently optionally substituted lower alkyl or optionally substituted heteroaryl.9. The compound of claim 8 , wherein one Ris lower alkyl and the other Ris heteroaryl substituted with one or more NHgroups.10. The compound of claim 8 , wherein one Ris lower alkyl and the other Ris pyrimidinyl substituted with one or more NHgroups.11. The compound of claim 10 , wherein one Ris t-butyl and the other Ris pyrimidinyl substituted with NH.13. The compound of claim 12 , wherein Ar is thiazolyl.14. The compound of claim 12 , wherein Ar is 4-thiazolyl.16. A pharmaceutical composition comprising: a compound of and a pharmaceutically acceptable carrier or excipient.17. A pharmaceutical composition comprising: a compound of and a pharmaceutically acceptable carrier or excipient.18. A pharmaceutical composition comprising a compound of and another therapeutic agent.19. A method for treating a subject suffering from melanoma claim 15 , thyroid cancer or colorectal cancer claim 15 , said method comprising: administering to the subject an effective amount of a compound of .20. The method of claim 19 , wherein the melanoma is melanoma having a mutation encoding a V600E amino acid substitution. This application is a continuation application of U.S. application Ser. No. 12/669,450, filed Jan ...

Подробнее
12-09-2013 дата публикации

Process for the synthesis of halogenated cyclic compounds

Номер: US20130237710A1
Автор: Max Braun
Принадлежит: SOLVAY SA

A process for the manufacture of a cyclic compound of formula (I) which comprises (a) adding an acid halide of formula R 1 —C (O)—X, to a vinyl ether of formula (II): CH 2 ═CH—OR 2 , to produce an addition product, and (b) reacting the addition product with a compound of formula (III): Y-A-Z; wherein R 1 is a halogenated alkyl group; wherein X is fluorine, chlorine, or bromine; wherein R 2 is an alkyl group, an aralkyl group, or an aryl group; wherein Z and Y designate independently carbon or a heteroatom; and wherein A is a linking group between Z and Y comprising 0, 1, 2 or 3 atoms in the cycle.

Подробнее
19-09-2013 дата публикации

PROLYL HYDROXYLASE INHIBITORS AND METHOD OF USE

Номер: US20130245076A1
Принадлежит:

The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia. 2. The compound according to claim 1 , wherein Ris —OR.3. The compound according to claim 2 , wherein Ris hydrogen.4. The compound according to claim 2 , wherein Ris methyl.5. The compound according to claim 1 , wherein Ris —NRR.6. The compound according to claim 5 , wherein Rand Rare each independently hydrogen or methyl.7. The compound according to claim 6 , wherein R is —NH.8. The compound {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid.10. The composition according to claim 9 , wherein Ris —OR.11. The composition according to claim 10 , wherein Ris hydrogen.12. The composition according to claim 10 , wherein Ris methyl.13. The composition according to claim 9 , wherein Ris —NRR.14. The composition according to claim 13 , wherein Rand Rare each independently hydrogen or methyl.15. The composition according to claim 14 , wherein R is —NH.16. The composition according to claim 9 , wherein the compound is {[5-(3-fluorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid.18. A method for treating anemia claim 1 , comprising administering to a subject a compound according to .19. A method for treating anemia claim 9 , comprising administering to a subject a composition according to .20. A method for treating anemia claim 17 , comprising administering to a subject a compound according to . This application is a Continuation application of U.S. application Ser. No. 13/681,876, filed Nov. 20, 2012, which is a Continuation application of U.S. application Ser. No. 12/860,073, filed Aug. 20, 2010, which is a Continuation application of U.S. application Ser. No. 11/821,936, now U.S. Pat. No. 7,811,595 B2, filed Jun. 26, 2007, which claims the benefit of ...

Подробнее
26-09-2013 дата публикации

SUBSTITUTED PHENOXYPYRIDINES

Номер: US20130252922A1
Автор: Hitchcock Marion
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to substituted phenoxypyridine compounds of general formula (I) in which R1, R2 and R3 are as defined in the claims, to methods of preparing said compounds, to intermediates for the preparation of said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 2. The compound according to claim 1 , wherein:{'sub': 1', '6', '2', '6', '3', '6, 'claim-text': a halogen atom, or a', {'sub': 1', '6', '1', '6', '2', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6', '1', '6', '3', '10', '1', '6', '1', '6', '1', '6', '1', '6', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '1', '6', '2', '1', '6', '2', '2', '2', '2', '2', '2, 'CN, C-C-alkyl-, halo-C-C-alkyl-, HN—C-C-alkyl-, R(R′)N—C-C-alkyl-, HO—C-C-alkyl, C-C-alkyl substituted with two OH groups, C-C-alkoxy-C-C-alkyl-, halo-C-C-alkoxy-C-C-alkyl-, C-C-cycloalkyl-C-C-alkyl-, 3- to 10-membered 3- to 7-membered heterocycloalkyl-C-C-alkyl-, aryl-C-C-alkyl-, heteroaryl-C-C-alkyl-, —C(═O)R, —C(═O)NH, —C(═O)N(H)R, —C(═O)N(R)R′, —C(═O)OH, —C(═O)OR, —NH, —N(H)R, —N(R)R′, —N(H)C(═O)H, —N(H)C(═O)R, —N(R)C(═O)R′, —N(H)C(═O)NH, —N(H)C(═O)N(H)R, —N(H)C(═O)N(R)R′, —N(R)C(═O)NH, —N(R)C(═O)N(H)R, —N(R)C(═O)N(R)R′, —N(H)C(═O)OR, —N(R)C(═O)OR, —NO, —N(H)S(═O)R, —N(R)S(═O)R′, —N(H)S(═O)NH, —N(H)S(═O)N(H)R, —N(H)S(═O)N(R)R′, —N(R)S(═O)NH, —N(R)S(═O)N(H)R′, —N(R)S(═O)N(R′)R″, —N(H)S(═O)R, —N(H)S(═O)—C3-C6-cycloalkyl, —N(R)S(═O)R′, —N(H)S(═O)NH, —N(H)S(═O)N(H)R, —N(H)S(═O)N(R)R′, —N(R)S(═O)NH, —N(R)S(═O)N(H)R, —N(R)S(═O)N(R′)R″, —N═S(═O)(R)R′, —OH, C-C-alkoxy-, —OC(═O)H, —OC(═O)R, —OC(═O)NH, —OC(═O)N(H)R, —OC(═O)N(R)R′, —OC(═O)OR, —SH, C-C-alkyl-S—, —SC(═O)NH, —SC(═O)N(H)R, ...

Подробнее
26-09-2013 дата публикации

PYRIDINONE ANTAGONISTS OF ALPHA-4 INTEGRINS

Номер: US20130252957A1
Принадлежит: Elan Pharmaceuticals, Inc.

The present invention provides compounds that are alpha4 integrin antagonists having a structure according to the following formula: 119.-. (canceled)20. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.21. A method of treating an inflammatory disease comprising administering to a mammalian subject in need thereof a pharmaceutically effective amount of a compound according to claim 29 , wherein the inflammatory disease is selected from the group consisting of asthma claim 29 , inflammatory bowel disease claim 29 , ulcerative colitis claim 29 , Crohn's disease claim 29 , multiple sclerosis claim 29 , rheumatoid arthritis claim 29 , tumor metastasis claim 29 , graft versus host disease claim 29 , and organ or tissue rejection.22. The method of claim 21 , wherein said inflammatory disease is a member selected from Crohn's disease and ulcerative colitis.23. An in vitro assay for measuring binding of an α4β1 or α4β7 integrin to an integrin ligand claim 21 , (i) binding the ligand to a surface;', {'claim-ref': {'@idref': 'CLM-00029', 'claim 29'}, '(ii) contacting the ligand with a cell expressing the integrin, in the presence of a compound of ; and'}, '(iii) measuring the amount of cells bound to the surface., 'wherein the assay comprises24. The assay according to claim 23 , wherein the integrin ligand is a member selected from fibronectin (FN) claim 23 , VCAM-1 claim 23 , osteopontin and MadCAM.25. (canceled)26. An in vitro assay for measuring binding of the compound to an α4β1 or α4β7 integrin in the presence of a candidate molecule claim 29 , wherein the assay comprises incubating the test molecule in the presence of a compound of labeled with a radioactive claim 29 , colorimetric or fluorescent label claim 29 , and measuring the amount of the labeled compound for binding to the integrin.27. An in vitro assay for identifying a candidate molecule capable of binding to α4β1 or α4β7 integrin claim 29 , wherein the assay ...

Подробнее
26-09-2013 дата публикации

5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF AS UROTENSIN II RECEPTOR ANTAGONISTS

Номер: US20130252974A1
Принадлежит: SANOFI

The present invention relates to 5,6-bisaryl-2-pyridinecarboxamides, to their preparation and to their therapeutic use as urotensin II receptor antagonists. 2. The compound of claim 1 , wherein:R4 represents a hydrogen atom;W represents a halogen atom;Z represents a (C1-C4) alkylene group;either, R1 represents a hydrogen atom and R2 represents a (C1-C4) alkyl group, or R1 and R2 form, together with the carbon atom to which they are attached, a monocyclic or polycyclic system selected from a (C3-C8) cycloalkyl group and a bridged tetracyclic group, wherein said monocyclic or polycyclic system is optionally substituted with one or more hydroxyl groups;either R3 represents a group C(O)R5, with R5 representing a (C1-C4) alkoxy group optionally substituted with a (C1-C4) alkoxy group or a group NR6R7, with R6 and R7, independently of each other, representing a hydrogen atom or a (C1-C4) alkyl, (C3-C5) cycloalkyl, (C1-C4) alkylsulfonyl, or haloalkyl group,{'sub': '2', 'or R3 represents a group CHXR8 in which X represents an oxygen atom and R8 represents a hydrogen atom or a (C1-C4) alkyl group,'}or R3 represents a nitrile group (CN).3. The compound of claim 1 , wherein:X represents a nitrogen atom and Y represents a nitrogen atom or —CR4-, in which R4 represents a hydrogen atom;A represents said fused aryl, unfused aryl, or heteroaryl group, wherein said aryl or heteroaryl group is optionally substituted with one or more groups selected from halogen atom, (C1-C4) alkyl, (C3-C5) cycloalkyl, (C1-C4) alkoxy, and haloalkoxy;W represents a halogen atom;Z represents a (C1-C4) alkylene group; andeither, R1 represents a hydrogen atom and R2 represents a (C1-C4) alkyl group, or R1 and R2 form, together with the carbon atom to which they are attached, a (C3-C8) cycloalkyl group optionally substituted with one or more hydroxyl groups or an adamantyl group;either R3 represents a group C(O)R5 with R5 representing a (C1-C4) alkoxy group optionally substituted with a (C1-C4) alkoxy ...

Подробнее
03-10-2013 дата публикации

SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS

Номер: US20130261120A1
Принадлежит: Bayer Intellectual Property GmbH

The present invention relates to: 3. The combination according to claim 1 , wherein:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'said component B is one or more N-(2-arylamino) aryl sulfonamide compounds of general formula (II) according to , which is selected from the list consisting ofExample 1: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-methanesulfonamide:Example 2: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)cyclopropanesulfonamide:Example 3: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)propane-2-sulfonamide:Example 4: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)butane-1-sulfonamide:Example 5: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2,2,2-trifluoro ethane sulfonamide:Example 6: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)butane-2-sulfonamide:Example 7: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-N-methyl cyclopropane sulfonamide:Example 8: 1-Chloro-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)methane sulfonamide:Example 9: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-2-methylpropane-2-sulfonamide:Example 10: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)cyclopentanesulfonamide:Example 11: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)cyclohexanesulfonamide:Example 12: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-methylcyclopropane-1-sulfonamide:Example 13: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide:Example 14: (S)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide:Example 15: (R)—N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide:Example 16: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide:Example 17: N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)-3-hydroxypropane-1-sulfonamide:Example 18: N-(3,4-difluoro-2-(2-fluoro-4- ...

Подробнее
03-10-2013 дата публикации

Therapeutic Compounds for Protozoal and Microbial Infections and Cancer

Номер: US20130261133A1
Принадлежит: The University of Montana

The compounds of the invention exhibit antiprotozoal, antimicrobial, and anticancer properties that are useful for the treatment or prevention of infections or cancer in a patient (e.g., a human). For example, the compounds and methods described herein can be used for the treatment or prevention of protozoal infections such as leishmaniasis, malaria, and infections, bacterial infections such as and , and cancers such as breast, colon, lung, or prostate cancer. The invention further provides methods of synthesizing such compounds as well as kits useful for administering the compounds. 2. The compound of claim 1 , wherein said compound is selected from the group consisting of (3S claim 1 ,8R)-8-hydroxyheptadeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3R claim 1 ,8R)-8-hydroxyheptadeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3R claim 1 ,8S)-8-hydroxyheptadeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3S claim 1 ,8R)-8-hydroxyhexadeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3S claim 1 ,8S)-8-hydroxyhexadeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3R claim 1 ,8R)-8-hydroxyhexadeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3R claim 1 ,8S)-8-hydroxyhexadeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3S claim 1 ,8R)-8-hydroxypentadeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3S claim 1 ,8S)-8-hydroxypentadeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3R claim 1 ,8R)-8-hydroxypentadeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3R claim 1 ,8S)-8-hydroxypentadeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3S claim 1 ,8R)-8-hydroxytetradeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3S claim 1 ,8S)-8-hydroxytetradeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3R claim 1 ,8R)-8-hydroxytetradeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3R claim 1 ,8S)-8-hydroxytetradeca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3S claim 1 ,8R)-8-hydroxytrideca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3S claim 1 ,8S)-8-hydroxytrideca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3R claim 1 ,8R)-8-hydroxytrideca-1-en-4 claim 1 ,6-diyn-3-yl acetate; (3R claim 1 , ...

Подробнее
10-10-2013 дата публикации

AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME

Номер: US20130267701A1
Принадлежит:

Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure 2. The compound according to claim 1 , wherein D claim 1 , Dand Dare independently CH or C substituted by one of the w R.3. The compound according to claim 1 , wherein x is 0.4. The compound according to claim 1 , wherein the ring system denoted by “B” is arylene or heteroarylene.6. The compound according to claim 1 , wherein J is —NR— or —NRC(O)—.7. The compound according to claim 1 , wherein J is —C(O)NR— or —C(O)—.9. The compound according to claim 1 , wherein Rand Rtogether with the nitrogen to which they are bound form Hca.10. The compound according to wherein Ris -Cak. This application is a continuation of U.S. patent application Ser. No. 13/194,810, filed Jul. 29, 2011, which in turn claims the benefit of the earlier filing date of U.S. Provisional Patent Application Ser. No. 61/368,928, filed Jul. 29, 2010, each of which is hereby incorporated herein by reference in its entirety.1. FieldThis disclosure relates generally to compounds, pharmaceutical compositions and methods of use of the compounds and compositions containing them. This disclosure relates more particularly to certain substituted pyridine compounds and pharmaceutical compositions thereof, and to methods of treating and preventing metabolic disorders such as type II diabetes, atherosclerosis and cardiovascular disease using certain substituted pyridine compounds.2. Technical BackgroundThe kinase 5″-AMP-activated protein kinase (AMPK) is well established as an important sensor and regulator of cellular energy homeostasis. Being a multi-substrate enzyme, AMPK regulates a variety of metabolic processes, such as glucose transport, glycolysis and lipid metabolism. It acts as a sensor of cellular energy homeostasis and is activated in response to certain hormones and muscle contraction as well as to intracellular metabolic stress signals such as ...

Подробнее
10-10-2013 дата публикации

Ampk-activating heterocyclic compounds and methods for using the same

Номер: US20130267702A1
Принадлежит: Rigel Pharmaceuticals Inc

Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure wherein E, J, T, the ring system denoted by “B”, T, R 3 , R 4 , w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.

Подробнее
17-10-2013 дата публикации

SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE

Номер: US20130273004A1
Принадлежит:

Selected heterocyclic compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. 4. The method of wherein said compound is N-(3 claim 1 ,3-dimethylindolin-6-yl) {2-[(4-pyridylmethyl)amino](3-pyridyl)}carboxamide and pharmaceutically acceptable salts thereof.5. The method of comprising a combination with a compound selected from antibiotic-type agents claim 1 , alkylating agents claim 1 , antimetabolite agents claim 1 , hormonal agents claim 1 , immunological agents claim 1 , interferon-type agents and miscellaneous agents. This application is a continuation of U.S. patent application Ser. No. 11/234,713, filed Sep. 23, 2005 which claims benefit of 10/046,681 filed Jan. 10, 2002 which claims benefit of U.S. Provisional Application Nos. 60/261,339, filed Jan. 12, 2001, and 60/323,764 filed Sep. 19, 2001 which are hereby incorporated by reference.This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer and angiogenesis-related disorders.Protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes, maintaining control over cellular function. A partial list of such kinases includes ab1, Atk, bcr-ab1, Blk, Brk, Btk, c-kit, c-met, c-src, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRaf1, CSF1R, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, ros, tie, tie2, TRK, Yes, and Zap70. Inhibition of such kinases has become an important therapeutic target.Certain ...

Подробнее
24-10-2013 дата публикации

Pyridone Derivatives

Номер: US20130281428A1
Принадлежит:

Novel compounds or salts thereof, or crystals thereof, which inhibit Axl and are useful for treating diseases caused by Axl hyperfunction, diseases associated with Axl hyperfunction and/or diseases accompanied by Axl hyperfunction are provided. Pyridone derivatives represented by the formula (1) having various substituents or salts thereof, or crystals thereof (where R, R, R, R, R, A, W, X and n in the formula (1) are as defined in the specification, respectively) are provided. 2. The compound or salt thereof of claim 1 , wherein A is a phenylene group.3. The compound or salt thereof of claim 1 , wherein W is C—R.4. The compound or salt thereof of claim 1 , wherein n is 0.5. The compound or salt thereof of claim 1 , wherein Ris a hydrogen atom.7. The compound N-{4-[2-Amino-5-(3 claim 1 ,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-5-(4-fluorophenyl)-4-oxo-1-(2 claim 1 ,2 claim 1 ,2-trifluoroethyl)-1 claim 1 ,4-dihydropyridine-3-carboxamide or a salt thereof.8. The compound N-{4-[2-Amino-5-(3 claim 1 ,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-5-(4-fluorophenyl)-4-oxo-1-(2 claim 1 ,2 claim 1 ,2-trifluoroethyl)-1 claim 1 ,4-dihydropyridine-3-carboxamide hydrochloride.9. Crystalline N-{4-[2-amino-5-(3 claim 1 ,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-5-(4-fluorophenyl)-4-oxo-1-(2 claim 1 ,2 claim 1 ,2-trifluoroethyl)-1 claim 1 ,4-dihydropyridine-3-carboxamide hydrochloride.1025-. (canceled)26. The crystalline N-{4-[2-amino-5-(3 claim 9 ,4-dimethoxyphenyl)pyridin-3-yl]phenyl}-5-(4-fluorophenyl)-4-oxo-1-(2 claim 9 ,2 claim 9 ,2-trifluoroethyl)-1 claim 9 ,4-dihydropyridine-3-carboxamide hydrochloride of claim 9 , which has characteristic peaks at diffraction angles 2θ of 7.44 claim 9 , 10.00 claim 9 , 13.48 claim 9 , 14.86 claim 9 , 16.10 claim 9 , 19.30 claim 9 , 20.30 claim 9 , 22.62 claim 9 , 23.02 claim 9 , 23.70 claim 9 , 24.54 claim 9 , 25.92 and 28.46 in a powder X-ray diffraction diagram obtained by irradiation with copper Kα radiation (wavelength λ=1.54 Å).27. The ...

Подробнее
31-10-2013 дата публикации

1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS

Номер: US20130289010A1
Принадлежит:

1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and/or treat certain diseases or conditions. 2. A method according to claim 1 , wherein R1 is —NHSOR4 claim 1 , wherein R4 is methyl claim 1 , R2 is —OR3 claim 1 , wherein R3 is cyclopropylmethyl claim 1 , and n is 0.3. A method according to claim 1 , wherein R1 is —NHSOR4 claim 1 , wherein R4 is methyl claim 1 , R2 is —OR3 claim 1 , wherein R3 is cyclopropylmethyl claim 1 , and n is 1.4. A method according to claim 1 , wherein R1 is —OR3 claim 1 , R2 is —NHSOR4 wherein R4 is methyl claim 1 , and n is 1.5. A method according to claim 1 , wherein R1 is methyl claim 1 , R2 is —NHSOR4 wherein R4 is methyl claim 1 , and n is 1.6. A method according to claim 1 , wherein both R1 and R2 are —NHSOR4 claim 1 , wherein R4 is methyl claim 1 , and n is 0.7. A method according to claim 1 , wherein both R1 and R2 are —NHSOR4 claim 1 , wherein R4 is methyl claim 1 , and n is 1.89-. (canceled)10. A method according to claim 1 , further comprising administering a second pharmaceutical active component selected from the group consisting of a β2 agonist claim 1 , an M3 antagonist claim 1 , and a corticosteroid.11. A method according to claim 10 , wherein said second active component is formoterol or carmoterol.12. A method according to claim 1 , comprising administering a pharmaceutical composition comprising a compound of formula (I) or a salt thereof and one or more pharmaceutically acceptable carriers and/or excipients.13. A method according to claim 1 , comprising administering a pharmaceutical composition comprising:a compound of formula (I) or a salt thereof;a second pharmaceutical active component selected from the group consisting of a β2 agonist, an M3 antagonist, and a corticosteroid; andone or more pharmaceutically acceptable carriers and/or excipients.14. A method according to claim 12 , wherein said administering is carried out with ...

Подробнее
31-10-2013 дата публикации

DERIVATIVES OF NICOTINIC ACID N-OXIDE, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ENZYME 3-HYDROXYANTHRANILATE-3, 4-DIOXYGENASE

Номер: US20130289081A1
Принадлежит:

A derivative of nicotinic acid N-oxide is described having formula (I): that acts as inhibitor of enzyme 3-hydroxyanthranilate-3,4-dioxygenase (3HAO), and is thus able to reduce QUIN biosynthesis in vivo under excitotoxic or pathological conditions, said compound being at the same time also chemically stable towards auto-oxidation. 113-. (canceled)15. The compound of claim 14 , wherein Rand Rare H; and{'sub': '1', 'Ris H, a halogen or a methyl group.'}20. The compound of and a pharmaceutically acceptable carrier.21. A method for inhibiting activity of 3-hydroxyanthranilate-3 claim 14 ,4-dioxygenase (3HAO) claim 14 , the method comprising:{'claim-ref': {'@idref': 'CLM-00014', 'claim 14'}, 'administering a compound according to in a therapeutic amount to treat a pathological condition ascribable to an excessive quinolinic acid (QUIN) production.'}22. The method of claim 21 , wherein the pathological condition is Alzheimer's disease claim 21 , Huntington's disease claim 21 , cerebral ischemia claim 21 , HIV-related dementia claim 21 , or neonatal hypoxia.26. A method for reducing levels of quinolinic acid (QUIN) claim 21 , the method comprising:{'claim-ref': {'@idref': 'CLM-00014', 'claim 14'}, 'administering to a subject in need thereof a compound according to in a therapeutic amount to reduce QUIN-induced neurotoxicity.'} The present invention concerns derivatives of nicotinic acid N-oxide, their preparation and their use as inhibitors of enzyme 3-hydroxyanthranilate-3,4-dioxygenase (3HAO), involved in the production, throughout the kynurenine pathway, of quinolinic acid (QUIN), an endogenous neurotoxin.The kynurenine pathway of the tryptophan catabolism has attracted a large interest in view of the notion that at least two metabolites throughout the route have sustained neuroactive properties in the central nervous system (CNS). In is particular, kynurenic acid (KYNA) is an allosteric modulator of the glycine site of the NMDA receptor and of the α7 nicotinic ...

Подробнее
07-11-2013 дата публикации

Novel Ureas for the Treatment and Prevention of Cancer

Номер: US20130296380A1
Автор: Wang Zhaoyin, YU Chunrong
Принадлежит: Beta Pharma Canada Inc.

A compound of Formula (I), salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by multiple kinases, such as raf, VEGFR, PDGFR, FLT-3, and c-Kit. 2. The compound of claim 1 , wherein Y is O claim 1 , S claim 1 , or NR.3. The compound of claim 2 , wherein Y is O or S.4. The compound of claim 1 , wherein Z and Z′ are each CH.5. The compound of claim 1 , wherein Rand Rare each independently alkyl or halo.6. The compound of claim 5 , wherein Rand Rare each independently halo.7. The compound of claim 6 , wherein Rand Rare each independently F claim 6 , Cl claim 6 , or Br.8. The compound of claim 1 , wherein Ris hydrogen claim 1 , halo claim 1 , carboxyl claim 1 , carboxyl ester claim 1 , or aminocarbonyl.9. The compound of claim 8 , wherein Ris aminocarbonyl.10. The compound of claim 9 , wherein Ris methylaminocarbonyl.11. The compound of claim 1 , wherein m and n are each independently 0 or 1.17. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of hydrochloric acid claim 1 , hydrobromic acid claim 1 , sulfuric acid claim 1 , phosphoric acid claim 1 , methanesulfonic acid claim 1 , trifluoromethanesulfonic acid claim 1 , benzenesulfonic acid claim 1 , p-toluene sulfonic acid (tosylate salt) claim 1 , 1-napthalene sulfonic acid claim 1 , 2-napthalene sulfonic acid claim 1 , acetic acid claim 1 , trifluoroacetic acid claim 1 , malic add claim 1 , tartaric acid claim 1 , citric acid claim 1 , lactic acid claim 1 , oxalic acid claim 1 , succinic acid claim 1 , fumaric acid claim 1 , maleic acid claim 1 , benzoic acid claim 1 , salicylic acid claim 1 , phenylacetic acid claim 1 , or mandelic acid.18. A pharmaceutical composition comprising a compound of and a physiologically acceptable carrier.19. A method for preventing or treating a disease in a mammal that is mediated by protein kinanse claim 1 , comprising ...

Подробнее
14-11-2013 дата публикации

Pyridine Compounds and the Uses Thereof

Номер: US20130303526A1
Принадлежит: Purdue Pharma LP

The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R 1a , A 1 , A 2 , E, G, Z 1 , and Z 2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.

Подробнее